<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">39456253</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>26</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>28</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2218-273X</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>10</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>17</Day></PubDate></JournalIssue><Title>Biomolecules</Title><ISOAbbreviation>Biomolecules</ISOAbbreviation></Journal><ArticleTitle>The Ambivalence of Post COVID-19 Vaccination Responses in Humans.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1320</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/biom14101320</ELocationID><Abstract><AbstractText>The Coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has prompted a massive global vaccination campaign, leading to the rapid development and deployment of several vaccines. Various COVID-19 vaccines are under different phases of clinical trials and include the whole virus or its parts like DNA, mRNA, or protein subunits administered directly or through vectors. Beginning in 2020, a few mRNA (Pfizer-BioNTech BNT162b2 and Moderna mRNA-1273) and adenovirus-based (AstraZeneca ChAdOx1-S and the Janssen Ad26.COV2.S) vaccines were recommended by WHO for emergency use before the completion of the phase 3 and 4 trials. These vaccines were mostly administered in two or three doses at a defined frequency between the two doses. While these vaccines, mainly based on viral nucleic acids or protein conferred protection against the progression of SARS-CoV-2 infection into severe COVID-19, and prevented death due to the disease, their use has also been accompanied by a plethora of side effects. Common side effects include localized reactions such as pain at the injection site, as well as systemic reactions like fever, fatigue, and headache. These symptoms are generally mild to moderate and resolve within a few days. However, rare but more serious side effects have been reported, including allergic reactions such as anaphylaxis and, in some cases, myocarditis or pericarditis, particularly in younger males. Ongoing surveillance and research efforts continue to refine the understanding of these adverse effects, providing critical insights into the risk-benefit profile of COVID-19 vaccines. Nonetheless, the overall safety profile supports the continued use of these vaccines in combating the pandemic, with regulatory agencies and health organizations emphasizing the importance of vaccination in preventing COVID-19's severe outcomes. In this review, we describe different types of COVID-19 vaccines and summarize various adverse effects due to autoimmune and inflammatory response(s) manifesting predominantly as cardiac, hematological, neurological, and psychological dysfunctions. The incidence, clinical presentation, risk factors, diagnosis, and management of different adverse effects and possible mechanisms contributing to these effects are discussed. The review highlights the potential ambivalence of human response post-COVID-19 vaccination and necessitates the need to mitigate the adverse side effects.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gopalaswamy</LastName><ForeName>Radha</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0001-8688-4617</Identifier><AffiliationInfo><Affiliation>Directorate of Distance Education, Madurai Kamaraj University, Madurai 625021, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aravindhan</LastName><ForeName>Vivekanandhan</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0002-5639-4948</Identifier><AffiliationInfo><Affiliation>Department of Genetics, Dr Arcot Lakshmanasamy Mudaliyar Post Graduate Institute of Basic Medical Sciences (Dr ALM PG IBMS), University of Madras, Taramani, Chennai 600005, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Subbian</LastName><ForeName>Selvakumar</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-2021-8632</Identifier><AffiliationInfo><Affiliation>Public Health Research Institute, New Jersey Medical School, Rutgers University, Newark, NJ 07103, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Biomolecules</MedlineTA><NlmUniqueID>101596414</NlmUniqueID><ISSNLinking>2218-273X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EPK39PL4R4</RegistryNumber><NameOfSubstance UI="D000090983">2019-nCoV Vaccine mRNA-1273</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000090982">BNT162 Vaccine</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000090983" MajorTopicYN="N">2019-nCoV Vaccine mRNA-1273</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000090982" MajorTopicYN="N">BNT162 Vaccine</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="Y">COVID-19 Vaccines</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Bell&#x2019;s palsy</Keyword><Keyword MajorTopicYN="N">Guillain&#x2013;Barr&#xe9; syndrome</Keyword><Keyword MajorTopicYN="N">adverse effects</Keyword><Keyword MajorTopicYN="N">allergy</Keyword><Keyword MajorTopicYN="N">autoimmunity</Keyword><Keyword MajorTopicYN="N">immune activation</Keyword><Keyword MajorTopicYN="N">long COVID</Keyword><Keyword MajorTopicYN="N">myocarditis</Keyword><Keyword MajorTopicYN="N">proinflammatory response</Keyword><Keyword MajorTopicYN="N">thrombosis</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>10</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>19</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>19</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>1</Hour><Minute>2</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>17</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39456253</ArticleId><ArticleId IdType="pmc">PMC11506738</ArticleId><ArticleId IdType="doi">10.3390/biom14101320</ArticleId><ArticleId IdType="pii">biom14101320</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>WHO  WHO COVID-19 Dashboard.  [(accessed on 15 September 2024)].  Available online:  https://data.who.int/dashboards/covid19/cases?n=c.</Citation></Reference><Reference><Citation>Cascella M., Rajnik M., Aleem A., Dulebohn S.C., Di Napoli R. StatPearls. StatPearls Publishing; Treasure Island, FL, USA: 2024. Features, Evaluation, and Treatment of Coronavirus (COVID-19)</Citation><ArticleIdList><ArticleId IdType="pubmed">32150360</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu B., Guo H., Zhou P., Shi Z.L. Characteristics of SARS-CoV-2 and COVID-19. Nat. Rev. Microbiol. 2021;19:141&#x2013;154. doi: 10.1038/s41579-020-00459-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-020-00459-7</ArticleId><ArticleId IdType="pmc">PMC7537588</ArticleId><ArticleId IdType="pubmed">33024307</ArticleId></ArticleIdList></Reference><Reference><Citation>da Rosa Mesquita R., Francelino Silva Junior L.C., Santos Santana F.M., Farias de Oliveira T., Campos Alcantara R., Monteiro Arnozo G., Rodrigues da Silva Filho E., Galdino Dos Santos A.G., Oliveira da Cunha E.J., Salgueiro de Aquino S.H., et al. Clinical manifestations of COVID-19 in the general population: Systematic review. Wien. Klin. Wochenschr. 2021;133:377&#x2013;382. doi: 10.1007/s00508-020-01760-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00508-020-01760-4</ArticleId><ArticleId IdType="pmc">PMC7689634</ArticleId><ArticleId IdType="pubmed">33242148</ArticleId></ArticleIdList></Reference><Reference><Citation>Markov P.V., Ghafari M., Beer M., Lythgoe K., Simmonds P., Stilianakis N.I., Katzourakis A. The evolution of SARS-CoV-2. Nat. Rev. Microbiol. 2023;21:361&#x2013;379. doi: 10.1038/s41579-023-00878-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-023-00878-2</ArticleId><ArticleId IdType="pubmed">37020110</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathew D.S., Pandya T., Pandya H., Vaghela Y., Subbian S. An Overview of SARS-CoV-2 Etiopathogenesis and Recent Developments in COVID-19 Vaccines. Biomolecules. 2023;13:1565. doi: 10.3390/biom13111565.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biom13111565</ArticleId><ArticleId IdType="pmc">PMC10669259</ArticleId><ArticleId IdType="pubmed">38002247</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramasamy S., Subbian S. Critical Determinants of Cytokine Storm and Type I Interferon Response in COVID-19 Pathogenesis. Clin. Microbiol. Rev. 2021;34:e00299-20. doi: 10.1128/CMR.00299-20.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/CMR.00299-20</ArticleId><ArticleId IdType="pmc">PMC8142516</ArticleId><ArticleId IdType="pubmed">33980688</ArticleId></ArticleIdList></Reference><Reference><Citation>Beijnen E.M.S., Odumade O.A., Haren S.D.V. Molecular Determinants of the Early Life Immune Response to COVID-19 Infection and Immunization. Vaccines. 2023;11:509. doi: 10.3390/vaccines11030509.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines11030509</ArticleId><ArticleId IdType="pmc">PMC10052886</ArticleId><ArticleId IdType="pubmed">36992093</ArticleId></ArticleIdList></Reference><Reference><Citation>Bian S., Li L., Wang Z., Cui L., Xu Y., Guan K., Zhao B. Allergic Reactions afterthe Administration of COVID-19 Vaccines. Front. Public Health. 2022;10:878081. doi: 10.3389/fpubh.2022.878081.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpubh.2022.878081</ArticleId><ArticleId IdType="pmc">PMC9152252</ArticleId><ArticleId IdType="pubmed">35655467</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwee T.C., Kwee R.M. Chest CT in COVID-19: What the Radiologist Needs to Know. Radiographics. 2020;40:1848&#x2013;1865. doi: 10.1148/rg.2020200159.</Citation><ArticleIdList><ArticleId IdType="doi">10.1148/rg.2020200159</ArticleId><ArticleId IdType="pmc">PMC7587296</ArticleId><ArticleId IdType="pubmed">33095680</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarkodie B.D., Mensah Y.B. CT scan chest findings in symptomatic COVID-19 patients: A reliable alternative for diagnosis. Ghana. Med. J. 2020;54:97&#x2013;99. doi: 10.4314/gmj.v54i4s.14.</Citation><ArticleIdList><ArticleId IdType="doi">10.4314/gmj.v54i4s.14</ArticleId><ArticleId IdType="pmc">PMC8087365</ArticleId><ArticleId IdType="pubmed">33976447</ArticleId></ArticleIdList></Reference><Reference><Citation>Dolinay T., Jun D., Maller A., Chung A., Grimes B., Hsu L., Nelson D., Villagas B., Kim G.H.J., Goldin J. Quantitative image analysis in COVID-19 acute respiratory distress syndrome: A cohort observational study. F1000Research. 2021;10:1266. doi: 10.12688/f1000research.75311.1.</Citation><ArticleIdList><ArticleId IdType="doi">10.12688/f1000research.75311.1</ArticleId><ArticleId IdType="pmc">PMC10182379</ArticleId><ArticleId IdType="pubmed">37224317</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang D.H., Kim G.H.J., Park S.B., Lee S.I., Koh J.S., Brown M.S., Abtin F., McNitt-Gray M.F., Goldin J.G., Lee J.S. Quantitative Computed Tomography Lung COVID Scores with Laboratory Markers: Utilization to Predict Rapid Progression and Monitor Longitudinal Changes in Patients with Coronavirus 2019 (COVID-19) Pneumonia. Biomedicines. 2024;12:120. doi: 10.3390/biomedicines12010120.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines12010120</ArticleId><ArticleId IdType="pmc">PMC10813449</ArticleId><ArticleId IdType="pubmed">38255225</ArticleId></ArticleIdList></Reference><Reference><Citation>Banerjee S., Banerjee D., Singh A., Kumar S., Pooja D., Ram V., Kulhari H., Saharan V.A. A Clinical Insight on New Discovered Molecules and Repurposed Drugs for the Treatment of COVID-19. Vaccines. 2023;11:332. doi: 10.3390/vaccines11020332.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines11020332</ArticleId><ArticleId IdType="pmc">PMC9967525</ArticleId><ArticleId IdType="pubmed">36851211</ArticleId></ArticleIdList></Reference><Reference><Citation>Akinosoglou K., Rigopoulos E.A., Kaiafa G., Daios S., Karlafti E., Ztriva E., Polychronopoulos G., Gogos C., Savopoulos C. Tixagevimab/Cilgavimab in SARS-CoV-2 Prophylaxis and Therapy: A Comprehensive Review of Clinical Experience. Viruses. 2022;15:118. doi: 10.3390/v15010118.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v15010118</ArticleId><ArticleId IdType="pmc">PMC9866621</ArticleId><ArticleId IdType="pubmed">36680160</ArticleId></ArticleIdList></Reference><Reference><Citation>Somersan-Karakaya S., Mylonakis E., Menon V.P., Wells J.C., Ali S., Sivapalasingam S., Sun Y., Bhore R., Mei J., Miller J., et al. Casirivimab and Imdevimab for the Treatment of Hospitalized Patients with COVID-19. J. Infect. Dis. 2022;227:23&#x2013;34. doi: 10.1093/infdis/jiac320.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiac320</ArticleId><ArticleId IdType="pmc">PMC9384575</ArticleId><ArticleId IdType="pubmed">35895508</ArticleId></ArticleIdList></Reference><Reference><Citation>Stadler E., Burgess M.T., Schlub T.E., Khan S.R., Chai K.L., McQuilten Z.K., Wood E.M., Polizzotto M.N., Kent S.J., Cromer D., et al. Monoclonal antibody levels and protection from COVID-19. Nat. Commun. 2023;14:4545. doi: 10.1038/s41467-023-40204-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-023-40204-1</ArticleId><ArticleId IdType="pmc">PMC10382502</ArticleId><ArticleId IdType="pubmed">37507368</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Y., Xiao Z., Ye K., He X., Sun B., Qin Z., Yu J., Yao J., Wu Q., Bao Z., et al. SARS-CoV-2: Characteristics and current advances in research. Virol. J. 2020;17:117. doi: 10.1186/s12985-020-01369-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12985-020-01369-z</ArticleId><ArticleId IdType="pmc">PMC7387805</ArticleId><ArticleId IdType="pubmed">32727485</ArticleId></ArticleIdList></Reference><Reference><Citation>Bahsoun A., Fakih Y., Zareef R., Bitar F., Arabi M. Corticosteroids in COVID-19: Pros and cons. Front Med. 2023;10:1202504. doi: 10.3389/fmed.2023.1202504.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2023.1202504</ArticleId><ArticleId IdType="pmc">PMC10461317</ArticleId><ArticleId IdType="pubmed">37644981</ArticleId></ArticleIdList></Reference><Reference><Citation>Gopalaswamy R., Subbian S. Corticosteroids for COVID-19 Therapy: Potential Implications on Tuberculosis. Int. J. Mol. Sci. 2021;22:3773. doi: 10.3390/ijms22073773.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22073773</ArticleId><ArticleId IdType="pmc">PMC8038708</ArticleId><ArticleId IdType="pubmed">33917321</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X., Mi Z., Liu Z., Rong P. SARS-CoV-2: Pathogenesis, therapeutics, variants, and vaccines. Front. Microbiol. 2024;15:1334152. doi: 10.3389/fmicb.2024.1334152.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2024.1334152</ArticleId><ArticleId IdType="pmc">PMC11208693</ArticleId><ArticleId IdType="pubmed">38939189</ArticleId></ArticleIdList></Reference><Reference><Citation>Soraci L., Lattanzio F., Soraci G., Gambuzza M.E., Pulvirenti C., Cozza A., Corsonello A., Luciani F., Rezza G. COVID-19 Vaccines: Current and Future Perspectives. Vaccines. 2022;10:608. doi: 10.3390/vaccines10040608.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines10040608</ArticleId><ArticleId IdType="pmc">PMC9025326</ArticleId><ArticleId IdType="pubmed">35455357</ArticleId></ArticleIdList></Reference><Reference><Citation>Gong W., Parkkila S., Wu X., Aspatwar A. SARS-CoV-2 variants and COVID-19 vaccines: Current challenges and future strategies. Int. Rev. Immunol. 2023;42:393&#x2013;414. doi: 10.1080/08830185.2022.2079642.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/08830185.2022.2079642</ArticleId><ArticleId IdType="pubmed">35635216</ArticleId></ArticleIdList></Reference><Reference><Citation>Grana C., Ghosn L., Evrenoglou T., Jarde A., Minozzi S., Bergman H., Buckley B.S., Probyn K., Villanueva G., Henschke N., et al. Efficacy and safety of COVID-19 vaccines. Cochrane Database Syst. Rev. 2022;12:CD015477. doi: 10.1002/14651858.CD015477.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD015477</ArticleId><ArticleId IdType="pmc">PMC9726273</ArticleId><ArticleId IdType="pubmed">36473651</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel R., Kaki M., Potluri V.S., Kahar P., Khanna D. A comprehensive review of SARS-CoV-2 vaccines: Pfizer, Moderna &amp; Johnson &amp; Johnson. Hum. Vaccin. Immunother. 2022;18:2002083. doi: 10.1080/21645515.2021.2002083.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2021.2002083</ArticleId><ArticleId IdType="pmc">PMC8862159</ArticleId><ArticleId IdType="pubmed">35130825</ArticleId></ArticleIdList></Reference><Reference><Citation>Rotshild V., Hirsh-Raccah B., Miskin I., Muszkat M., Matok I. Comparing the clinical efficacy of COVID-19 vaccines: A systematic review and network meta-analysis. Sci. Rep. 2021;11:22777. doi: 10.1038/s41598-021-02321-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-02321-z</ArticleId><ArticleId IdType="pmc">PMC8611039</ArticleId><ArticleId IdType="pubmed">34815503</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu X., Xu K., Zhan P., Liu H., Zhang F., Song Y., Lv T. Comparative efficacy and safety of COVID-19 vaccines in phase III trials: A network meta-analysis. BMC Infect. Dis. 2024;24:234. doi: 10.1186/s12879-023-08754-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-023-08754-3</ArticleId><ArticleId IdType="pmc">PMC10880292</ArticleId><ArticleId IdType="pubmed">38383356</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO  World Health Organization (WHO) 12 Vaccines Granted Emergency Use Listing (EUL) by WHO.  [(accessed on 15 September 2024)].  Available online:  https://covid19.trackvaccines.org/agency/who/</Citation></Reference><Reference><Citation>Han X., Xu P., Ye Q. Analysis of COVID-19 vaccines: Types, thoughts, and application. J. Clin. Lab. Anal. 2021;35:e23937. doi: 10.1002/jcla.23937.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcla.23937</ArticleId><ArticleId IdType="pmc">PMC8418485</ArticleId><ArticleId IdType="pubmed">34396586</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y.D., Chi W.Y., Su J.H., Ferrall L., Hung C.F., Wu T.C. Coronavirus vaccine development: From SARS and MERS to COVID-19. J. Biomed. Sci. 2020;27:104. doi: 10.1186/s12929-020-00695-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12929-020-00695-2</ArticleId><ArticleId IdType="pmc">PMC7749790</ArticleId><ArticleId IdType="pubmed">33341119</ArticleId></ArticleIdList></Reference><Reference><Citation>Muhar B.K., Nehira J., Malhotra A., Kotchoni S.O. The Race for COVID-19 Vaccines: The Various Types and Their Strengths and Weaknesses. J. Pharm. Pract. 2023;36:953&#x2013;966. doi: 10.1177/08971900221097248.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/08971900221097248</ArticleId><ArticleId IdType="pmc">PMC9207585</ArticleId><ArticleId IdType="pubmed">35723017</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO  Interim Recommendations for Use of the Moderna mRNA-1273 Vaccine against COVID-19: Interim Guidance. 25 January 2021.  [(accessed on 15 September 2024)].  Available online:  https://www.who.int/publications/i/item/WHO-2019-nCoV-vaccines-SAGE-recommendation-mRNA-1273-2021.3.</Citation></Reference><Reference><Citation>WHO  Interim Recommendations for Use of the Pfizer&#x2013;BioNTech COVID-19 Vaccine, BNT162b2, under Emergency Use Listing: Interim Guidance. 8 January 2021.  [(accessed on 15 September 2024)].  Available online:  https://www.who.int/publications/i/item/WHO-2019-nCoV-vaccines-SAGE_recommendation-BNT162b2-2021.1.</Citation></Reference><Reference><Citation>WHO  Interim Recommendations for the Use of the Janssen Ad26.COV2.S.  [(accessed on 15 September 2024)].  Available online:  https://iris.who.int/handle/10665/340203.</Citation></Reference><Reference><Citation>WHO  Interim Recommendations for Use of the ChAdOx1-S Vaccine against COVID-19.  [(accessed on 15 September 2024)].  Available online:  https://iris.who.int/handle/10665/343388.</Citation></Reference><Reference><Citation>Fayad D., Frenck R.W., Jr. COVID-19 Vaccines in Children. J. Clin. Med. 2023;13:87. doi: 10.3390/jcm13010087.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm13010087</ArticleId><ArticleId IdType="pmc">PMC10779890</ArticleId><ArticleId IdType="pubmed">38202094</ArticleId></ArticleIdList></Reference><Reference><Citation>CDC  COVID-19 Vaccination Coverage and Demographic Characteristics of Infants and Children Aged 6 Months&#x2013;4 Years&#x2014;United States, 20 June &#x2013;31 December 2022.  [(accessed on 15 September 2024)]; Available online:  https://www.cdc.gov/mmwr/volumes/72/wr/mm7207a4.htm.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9949848</ArticleId><ArticleId IdType="pubmed">36795658</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen K.H., McChesney C., Rodriguez C., Vasudevan L., Bednarczyk R.A., Corlin L. Child and adolescent COVID-19 vaccination coverage by educational setting, United States. Public Health. 2024;229:126&#x2013;134. doi: 10.1016/j.puhe.2024.01.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.puhe.2024.01.029</ArticleId><ArticleId IdType="pmc">PMC10961195</ArticleId><ArticleId IdType="pubmed">38430658</ArticleId></ArticleIdList></Reference><Reference><Citation>CDC  COVID-19 Vaccination for People Who Are Pregnant or Breastfeeding.  [(accessed on 15 September 2024)]; Available online:  https://www.cdc.gov/covid/vaccines/pregnant-or-breastfeeding.html.</Citation></Reference><Reference><Citation>AbdelWareth L., Alhousani F., Abuyadek R., Donnelly J., Leinberger-Jabari A., Atef S., Al-Rifai R.H. Natural infection versus hybrid (natural and vaccination) humoral immune response to SARS-CoV-2: A comparative paired analysis. Front. Immunol. 2023;14:1230974. doi: 10.3389/fimmu.2023.1230974.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2023.1230974</ArticleId><ArticleId IdType="pmc">PMC10502301</ArticleId><ArticleId IdType="pubmed">37720219</ArticleId></ArticleIdList></Reference><Reference><Citation>Bobrovitz N., Ware H., Ma X., Li Z., Hosseini R., Cao C., Selemon A., Whelan M., Premji Z., Issa H., et al. Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the omicron variant and severe disease: A systematic review and meta-regression. Lancet Infect. Dis. 2023;23:556&#x2013;567. doi: 10.1016/S1473-3099(22)00801-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(22)00801-5</ArticleId><ArticleId IdType="pmc">PMC10014083</ArticleId><ArticleId IdType="pubmed">36681084</ArticleId></ArticleIdList></Reference><Reference><Citation>Suntronwong N., Kanokudom S., Auphimai C., Thongmee T., Assawakosri S., Vichaiwattana P., Yorsaeng R., Duangchinda T., Chantima W., Pakchotanon P., et al. Long-Term Dynamic Changes in Hybrid Immunity over Six Months after Inactivated and Adenoviral Vector Vaccination in Individuals with Previous SARS-CoV-2 Infection. Vaccines. 2024;12:180. doi: 10.3390/vaccines12020180.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines12020180</ArticleId><ArticleId IdType="pmc">PMC10891631</ArticleId><ArticleId IdType="pubmed">38400163</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO  Interim Statement on Hybrid Immunity and Increasing Population Seroprevalence Rates.  [(accessed on 15 September 2024)].  Available online:  https://www.who.int/news/item/01-06-2022-interim-statement-on-hybrid-immunity-and-increasing-population-seroprevalence-rates.</Citation></Reference><Reference><Citation>Kulczynski B., Skonieczny J. Case of localized form of respiratory tract amyloidosis with double localization. Otolaryngol. Pol. 1973;27:397&#x2013;400.</Citation><ArticleIdList><ArticleId IdType="pubmed">4729549</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaur R.J., Dutta S., Bhardwaj P., Charan J., Dhingra S., Mitra P., Singh K., Yadav D., Sharma P., Misra S. Adverse Events Reported fromCOVID-19 Vaccine Trials: A Systematic Review. Indian J. Clin. Biochem. 2021;36:427&#x2013;439. doi: 10.1007/s12291-021-00968-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12291-021-00968-z</ArticleId><ArticleId IdType="pmc">PMC7997788</ArticleId><ArticleId IdType="pubmed">33814753</ArticleId></ArticleIdList></Reference><Reference><Citation>CDC  Vaccine Safety System.  [(accessed on 15 September 2024)]; Available online:  https://www.cdc.gov/vaccine-safety-systems/index.html.</Citation></Reference><Reference><Citation>Rafaniello C., Gaio M., Zinzi A., Sullo M.G., Liguori V., Ferraro M., Petronzelli F., Felicetti P., Marchione P., Marra A.R., et al. Disentangling a Thorny Issue: Myocarditis and Pericarditis Post COVID-19 and Following mRNA COVID-19 Vaccines. Pharmaceuticals. 2022;15:525. doi: 10.3390/ph15050525.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ph15050525</ArticleId><ArticleId IdType="pmc">PMC9145505</ArticleId><ArticleId IdType="pubmed">35631352</ArticleId></ArticleIdList></Reference><Reference><Citation>Munjal J.S., Flores S.M., Yousuf H., Gupta V., Munjal R.S., Anamika F., Mendpara V., Shah P., Jain R. COVID-19 Vaccine-induced Myocarditis. J. Community Hosp. Intern. Med. Perspect. 2023;13:44&#x2013;49. doi: 10.55729/2000-9666.1229.</Citation><ArticleIdList><ArticleId IdType="doi">10.55729/2000-9666.1229</ArticleId><ArticleId IdType="pmc">PMC10589044</ArticleId><ArticleId IdType="pubmed">37868673</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo W., Deguise J., Tian Y., Huang P.C., Goru R., Yang Q., Peng S., Zhang L., Zhao L., Xie J., et al. Profiling COVID-19 Vaccine Adverse Events by Statistical and Ontological Analysis of VAERS Case Reports. Front. Pharmacol. 2022;13:870599. doi: 10.3389/fphar.2022.870599.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2022.870599</ArticleId><ArticleId IdType="pmc">PMC9263450</ArticleId><ArticleId IdType="pubmed">35814246</ArticleId></ArticleIdList></Reference><Reference><Citation>Alami A., Villeneuve P.J., Farrell P.J., Mattison D., Farhat N., Haddad N., Wilson K., Gravel C.A., Crispo J.A.G., Perez-Lloret S., et al. Myocarditis and Pericarditis Post-mRNA COVID-19 Vaccination: Insights from a Pharmacovigilance Perspective. J. Clin. Med. 2023;12:4971. doi: 10.3390/jcm12154971.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm12154971</ArticleId><ArticleId IdType="pmc">PMC10419493</ArticleId><ArticleId IdType="pubmed">37568373</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian F., Yang R., Chen Z. Safety and efficacy of COVID-19 vaccines in children and adolescents: A systematic review of randomized controlled trials. J. Med. Virol. 2022;94:4644&#x2013;4653. doi: 10.1002/jmv.27940.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.27940</ArticleId><ArticleId IdType="pmc">PMC9350282</ArticleId><ArticleId IdType="pubmed">35705969</ArticleId></ArticleIdList></Reference><Reference><Citation>Ciapponi A., Berrueta M., Parker E.P., Bardach A., Mazzoni A., Anderson S.A., Argento F.J., Ballivian J., Bok K., Comande D., et al. Safety of COVID-19 vaccines during pregnancy: A systematic review and meta-analysis. Vaccine. 2023;41:3688&#x2013;3700. doi: 10.1016/j.vaccine.2023.03.038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2023.03.038</ArticleId><ArticleId IdType="pmc">PMC10040368</ArticleId><ArticleId IdType="pubmed">37012114</ArticleId></ArticleIdList></Reference><Reference><Citation>Marchand G., Masoud A.T., Grover S., King A., Brazil G., Ulibarri H., Parise J., Arroyo A., Coriell C., Goetz S., et al. Maternal and neonatal outcomes of COVID-19 vaccination during pregnancy, a systematic review and meta-analysis. NPJ Vaccines. 2023;8:103. doi: 10.1038/s41541-023-00698-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41541-023-00698-8</ArticleId><ArticleId IdType="pmc">PMC10349851</ArticleId><ArticleId IdType="pubmed">37454153</ArticleId></ArticleIdList></Reference><Reference><Citation>Norman M., Magnus M.C., Soderling J., Juliusson P.B., Naver L., Ortqvist A.K., Haberg S., Stephansson O. Neonatal Outcomes afterCOVID-19 Vaccination in Pregnancy. JAMA. 2024;331:396&#x2013;407. doi: 10.1001/jama.2023.26945.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2023.26945</ArticleId><ArticleId IdType="pmc">PMC10848052</ArticleId><ArticleId IdType="pubmed">38319332</ArticleId></ArticleIdList></Reference><Reference><Citation>Piekos S.N., Hwang Y.M., Roper R.T., Sorensen T., Price N.D., Hood L., Hadlock J.J. Effect of COVID-19 vaccination and booster on maternal-fetal outcomes: A retrospective cohort study. Lancet Digit. Health. 2023;5:e594&#x2013;e606. doi: 10.1016/S2589-7500(23)00093-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2589-7500(23)00093-6</ArticleId><ArticleId IdType="pmc">PMC10473855</ArticleId><ArticleId IdType="pubmed">37537121</ArticleId></ArticleIdList></Reference><Reference><Citation>Goruntla N., Karisetty B., Nandini N., Bhupasamudram B., Gangireddy H.R., Veerabhadrappa K.V., Ezeonwumelu J.O.C., Bandaru V. Adverse events following COVID-19 vaccination among pregnant women attending primary health centers: An active-surveillance study. Vacunas. 2023 doi: 10.1016/j.vacun.2023.05.003. ahead of print .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vacun.2023.05.003</ArticleId><ArticleId IdType="pmc">PMC10192595</ArticleId><ArticleId IdType="pubmed">37362835</ArticleId></ArticleIdList></Reference><Reference><Citation>Lam J.N., Nehira J., Phung O., Deng B. Systematic Review: Safety and Efficacy of mRNA COVID-19 Vaccines in Pregnant Women. J. Pharm. Pract. 2024;37:967&#x2013;976. doi: 10.1177/08971900231196065.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/08971900231196065</ArticleId><ArticleId IdType="pubmed">37605626</ArticleId></ArticleIdList></Reference><Reference><Citation>Munro A.P.S., Feng S., Janani L., Cornelius V., Aley P.K., Babbage G., Baxter D., Bula M., Cathie K., Chatterjee K., et al. Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): A multicentre, blinded, phase 2, randomised trial. Lancet Infect. Dis. 2022;22:1131&#x2013;1141. doi: 10.1016/S1473-3099(22)00271-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(22)00271-7</ArticleId><ArticleId IdType="pmc">PMC9084623</ArticleId><ArticleId IdType="pubmed">35550261</ArticleId></ArticleIdList></Reference><Reference><Citation>Munro A.P.S., Janani L., Cornelius V., Aley P.K., Babbage G., Baxter D., Bula M., Cathie K., Chatterjee K., Dodd K., et al. Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): A blinded, multicentre, randomised, controlled, phase 2 trial. Lancet. 2021;398:2258&#x2013;2276. doi: 10.1016/S0140-6736(21)02717-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)02717-3</ArticleId><ArticleId IdType="pmc">PMC8639161</ArticleId><ArticleId IdType="pubmed">34863358</ArticleId></ArticleIdList></Reference><Reference><Citation>Stuart A.S.V., Shaw R.H., Liu X., Greenland M., Aley P.K., Andrews N.J., Cameron J.C., Charlton S., Clutterbuck E.A., Collins A.M., et al. Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): A single-blind, randomised, phase 2, non-inferiority trial. Lancet. 2022;399:36&#x2013;49. doi: 10.1016/S0140-6736(21)02718-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)02718-5</ArticleId><ArticleId IdType="pmc">PMC8648333</ArticleId><ArticleId IdType="pubmed">34883053</ArticleId></ArticleIdList></Reference><Reference><Citation>Pakki T.R., Mariana N., Tampubolon M.L., Rusli A., Romadhona S., Intan A.D., Chohan Z., Widiantari A.D., Herlina H., Puspitasari A., et al. Side Effects after mRNA COVID-19 Vaccine as a Booster in Health Workers. Iran. J. Public Health. 2022;51:2504&#x2013;2509. doi: 10.18502/ijph.v51i11.11167.</Citation><ArticleIdList><ArticleId IdType="doi">10.18502/ijph.v51i11.11167</ArticleId><ArticleId IdType="pmc">PMC9745411</ArticleId><ArticleId IdType="pubmed">36561250</ArticleId></ArticleIdList></Reference><Reference><Citation>Menni C., May A., Polidori L., Louca P., Wolf J., Capdevila J., Hu C., Ourselin S., Steves C.J., Valdes A.M., et al. COVID-19 vaccine waning and effectiveness and side-effects of boosters: A prospective community study from the ZOE COVID Study. Lancet Infect. Dis. 2022;22:1002&#x2013;1010. doi: 10.1016/S1473-3099(22)00146-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(22)00146-3</ArticleId><ArticleId IdType="pmc">PMC8993156</ArticleId><ArticleId IdType="pubmed">35405090</ArticleId></ArticleIdList></Reference><Reference><Citation>Hung S.I., Preclaro I.A.C., Chung W.H., Wang C.W. Immediate Hypersensitivity Reactions Induced by COVID-19 Vaccines: Current Trends, Potential Mechanisms and Prevention Strategies. Biomedicines. 2022;10:1260. doi: 10.3390/biomedicines10061260.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines10061260</ArticleId><ArticleId IdType="pmc">PMC9219714</ArticleId><ArticleId IdType="pubmed">35740283</ArticleId></ArticleIdList></Reference><Reference><Citation>Picard M., Stone C.A., Jr., Greenhawt M. Management of patients with immediate reactions to COVID-19 vaccines. J. Allergy Clin. Immunol. 2023;151:413&#x2013;415. doi: 10.1016/j.jaci.2022.09.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2022.09.003</ArticleId><ArticleId IdType="pmc">PMC9519382</ArticleId><ArticleId IdType="pubmed">36089078</ArticleId></ArticleIdList></Reference><Reference><Citation>Control C.f.D. Interim Considerations: Preparing for the Potential Management of Anaphylaxis after COVID-19 Vaccination.  [(accessed on 15 September 2024)]; Available online:  https://www.cdc.gov/vaccines/covid-19/clinical-considerations/managing-anaphylaxis.html.</Citation></Reference><Reference><Citation>Laisuan W. COVID-19 Vaccine Anaphylaxis: Current Evidence and Future Approaches. Front. Allergy. 2021;2:801322. doi: 10.3389/falgy.2021.801322.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/falgy.2021.801322</ArticleId><ArticleId IdType="pmc">PMC8974674</ArticleId><ArticleId IdType="pubmed">35387045</ArticleId></ArticleIdList></Reference><Reference><Citation>Control C.F.D. Recognizing and Responding to Anaphylaxis.  [(accessed on 15 September 2024)]; Available online:  https://stacks.cdc.gov/view/cdc/106312.</Citation></Reference><Reference><Citation>Sobczak M., Pawliczak R. The risk of anaphylaxis behind authorized COVID-19 vaccines: A meta-analysis. Clin. Mol. Allergy. 2022;20:1. doi: 10.1186/s12948-022-00167-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12948-022-00167-y</ArticleId><ArticleId IdType="pmc">PMC8762434</ArticleId><ArticleId IdType="pubmed">35039051</ArticleId></ArticleIdList></Reference><Reference><Citation>Boufidou F., Hatziantoniou S., Theodoridou K., Maltezou H.C., Vasileiou K., Anastassopoulou C., Medic S., Tsakris A. Anaphylactic Reactions to COVID-19 Vaccines: An Updated Assessment Based on Pharmacovigilance Data. Vaccines. 2023;11:613. doi: 10.3390/vaccines11030613.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines11030613</ArticleId><ArticleId IdType="pmc">PMC10051410</ArticleId><ArticleId IdType="pubmed">36992197</ArticleId></ArticleIdList></Reference><Reference><Citation>Wenande E., Garvey L.H. Immediate-type hypersensitivity to polyethylene glycols: A review. Clin. Exp. Allergy. 2016;46:907&#x2013;922. doi: 10.1111/cea.12760.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cea.12760</ArticleId><ArticleId IdType="pubmed">27196817</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruusgaard-Mouritsen M.A., Johansen J.D., Garvey L.H. Clinical manifestations and impact on daily life of allergy to polyethylene glycol (PEG) in ten patients. Clin. Exp. Allergy. 2021;51:463&#x2013;470. doi: 10.1111/cea.13822.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cea.13822</ArticleId><ArticleId IdType="pubmed">33394522</ArticleId></ArticleIdList></Reference><Reference><Citation>Swetha K., Kotla N.G., Tunki L., Jayaraj A., Bhargava S.K., Hu H., Bonam S.R., Kurapati R. Recent Advances in the Lipid Nanoparticle-Mediated Delivery of mRNA Vaccines. Vaccines. 2023;11:658. doi: 10.3390/vaccines11030658.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines11030658</ArticleId><ArticleId IdType="pmc">PMC10059764</ArticleId><ArticleId IdType="pubmed">36992242</ArticleId></ArticleIdList></Reference><Reference><Citation>Horejs C. From lipids to lipid nanoparticles to mRNA vaccines. Nat. Rev. Mater. 2021;6:1075&#x2013;1076. doi: 10.1038/s41578-021-00379-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41578-021-00379-9</ArticleId><ArticleId IdType="pmc">PMC8454296</ArticleId><ArticleId IdType="pubmed">34567796</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicaise-Roland P., Granger V., Soria A., Barbaud A., Pallardy M., Chollet-Martin S., de Chaisemartin L. Immediate hypersensitivity to COVID-19 vaccines: Focus on biological diagnosis. Front. Allergy. 2022;3:1007602. doi: 10.3389/falgy.2022.1007602.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/falgy.2022.1007602</ArticleId><ArticleId IdType="pmc">PMC9561365</ArticleId><ArticleId IdType="pubmed">36249342</ArticleId></ArticleIdList></Reference><Reference><Citation>Luxi N., Giovanazzi A., Arcolaci A., Bonadonna P., Crivellaro M.A., Cutroneo P.M., Ferrajolo C., Furci F., Guidolin L., Moretti U., et al. Allergic Reactions to COVID-19 Vaccines: Risk Factors, Frequency, Mechanisms and Management. BioDrugs. 2022;36:443&#x2013;458. doi: 10.1007/s40259-022-00536-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40259-022-00536-8</ArticleId><ArticleId IdType="pmc">PMC9190452</ArticleId><ArticleId IdType="pubmed">35696066</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Q., Jacobs T.M., McCallen J.D., Moore D.T., Huckaby J.T., Edelstein J.N., Lai S.K. Analysis of Pre-existing IgG and IgM Antibodies against Polyethylene Glycol (PEG) in the General Population. Anal. Chem. 2016;88:11804&#x2013;11812. doi: 10.1021/acs.analchem.6b03437.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.analchem.6b03437</ArticleId><ArticleId IdType="pmc">PMC6512330</ArticleId><ArticleId IdType="pubmed">27804292</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen B.M., Su Y.C., Chang C.J., Burnouf P.A., Chuang K.H., Chen C.H., Cheng T.L., Chen Y.T., Wu J.Y., Roffler S.R. Measurement of Pre-Existing IgG and IgM Antibodies against Polyethylene Glycol in Healthy Individuals. Anal. Chem. 2016;88:10661&#x2013;10666. doi: 10.1021/acs.analchem.6b03109.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.analchem.6b03109</ArticleId><ArticleId IdType="pubmed">27726379</ArticleId></ArticleIdList></Reference><Reference><Citation>Kozma G.T., Meszaros T., Berenyi P., Facsko R., Patko Z., Olah C.Z., Nagy A., Fulop T.G., Glatter K.A., Radovits T., et al. Role of anti-polyethylene glycol (PEG) antibodies in the allergic reactions to PEG-containing COVID-19 vaccines: Evidence for immunogenicity of PEG. Vaccine. 2023;41:4561&#x2013;4570. doi: 10.1016/j.vaccine.2023.06.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2023.06.009</ArticleId><ArticleId IdType="pmc">PMC10239905</ArticleId><ArticleId IdType="pubmed">37330369</ArticleId></ArticleIdList></Reference><Reference><Citation>Risma K.A., Edwards K.M., Hummell D.S., Little F.F., Norton A.E., Stallings A., Wood R.A., Milner J.D. Potential mechanisms of anaphylaxis to COVID-19 mRNA vaccines. J. Allergy Clin. Immunol. 2021;147:2075&#x2013;2082 e2072. doi: 10.1016/j.jaci.2021.04.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2021.04.002</ArticleId><ArticleId IdType="pmc">PMC8056854</ArticleId><ArticleId IdType="pubmed">33857566</ArticleId></ArticleIdList></Reference><Reference><Citation>Ndeupen S., Qin Z., Jacobsen S., Estanbouli H., Bouteau A., Igyarto B.Z. The mRNA-LNP platform&#x2019;s lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory. bioRxiv. 2021;24:103479. doi: 10.1101/2021.03.04.430128.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.03.04.430128</ArticleId><ArticleId IdType="pmc">PMC8604799</ArticleId><ArticleId IdType="pubmed">34841223</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamprinou M., Sachinidis A., Stamoula E., Vavilis T., Papazisis G. COVID-19 vaccines adverse events: Potential molecular mechanisms. Immunol. Res. 2023;71:356&#x2013;372. doi: 10.1007/s12026-023-09357-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12026-023-09357-5</ArticleId><ArticleId IdType="pmc">PMC9821369</ArticleId><ArticleId IdType="pubmed">36607502</ArticleId></ArticleIdList></Reference><Reference><Citation>Kounis N.G., Koniari I., de Gregorio C., Velissaris D., Petalas K., Brinia A., Assimakopoulos S.F., Gogos C., Kouni S.N., Kounis G.N., et al. Allergic Reactions to Current Available COVID-19 Vaccinations: Pathophysiology, Causality, and Therapeutic Considerations. Vaccines. 2021;9:221. doi: 10.3390/vaccines9030221.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines9030221</ArticleId><ArticleId IdType="pmc">PMC7999280</ArticleId><ArticleId IdType="pubmed">33807579</ArticleId></ArticleIdList></Reference><Reference><Citation>Lapidot M.B. Does the brain age uniformly? Evidence from effects of smooth pursuit eye movements on verbal and visual tasks. J. Gerontol. 1987;42:329&#x2013;331. doi: 10.1093/geronj/42.3.329.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/geronj/42.3.329</ArticleId><ArticleId IdType="pubmed">3571870</ArticleId></ArticleIdList></Reference><Reference><Citation>Basso C., Leone O., Rizzo S., De Gaspari M., van der Wal A.C., Aubry M.C., Bois M.C., Lin P.T., Maleszewski J.J., Stone J.R. Pathological features of COVID-19-associated myocardial injury: A multicentre cardiovascular pathology study. Eur. Heart J. 2020;41:3827&#x2013;3835. doi: 10.1093/eurheartj/ehaa664.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehaa664</ArticleId><ArticleId IdType="pmc">PMC7543528</ArticleId><ArticleId IdType="pubmed">32968776</ArticleId></ArticleIdList></Reference><Reference><Citation>Costa C., Moniati F. The Epidemiology of COVID-19 Vaccine-Induced Myocarditis. Adv. Med. 2024;2024:4470326. doi: 10.1155/2024/4470326.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2024/4470326</ArticleId><ArticleId IdType="pmc">PMC11045291</ArticleId><ArticleId IdType="pubmed">38681683</ArticleId></ArticleIdList></Reference><Reference><Citation>Furqan M., Chawla S., Majid M., Mazumdar S., Mahalwar G., Harmon E., Klein A. COVID-19 Vaccine-Related Myocardial and Pericardial Inflammation. Curr. Cardiol. Rep. 2022;24:2031&#x2013;2041. doi: 10.1007/s11886-022-01801-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11886-022-01801-6</ArticleId><ArticleId IdType="pmc">PMC9703393</ArticleId><ArticleId IdType="pubmed">36441403</ArticleId></ArticleIdList></Reference><Reference><Citation>Goyal M., Ray I., Mascarenhas D., Kunal S., Sachdeva R.A., Ish P. Myocarditis post-SARS-CoV-2 vaccination: A systematic review. QJM. 2023;116:7&#x2013;25. doi: 10.1093/qjmed/hcac064.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/qjmed/hcac064</ArticleId><ArticleId IdType="pmc">PMC8903459</ArticleId><ArticleId IdType="pubmed">35238384</ArticleId></ArticleIdList></Reference><Reference><Citation>Park J.H., Kim K.H. COVID-19 Vaccination-Related Myocarditis: What We Learned fromOur Experience and What We Need to Do in The Future. Korean Circ. J. 2024;54:295&#x2013;310. doi: 10.4070/kcj.2024.0065.</Citation><ArticleIdList><ArticleId IdType="doi">10.4070/kcj.2024.0065</ArticleId><ArticleId IdType="pmc">PMC11169908</ArticleId><ArticleId IdType="pubmed">38654456</ArticleId></ArticleIdList></Reference><Reference><Citation>Patone M., Mei X.W., Handunnetthi L., Dixon S., Zaccardi F., Shankar-Hari M., Watkinson P., Khunti K., Harnden A., Coupland C.A.C., et al. Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection. Nat. Med. 2022;28:410&#x2013;422. doi: 10.1038/s41591-021-01630-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01630-0</ArticleId><ArticleId IdType="pmc">PMC8863574</ArticleId><ArticleId IdType="pubmed">34907393</ArticleId></ArticleIdList></Reference><Reference><Citation>Rose J., Hulscher N., McCullough P.A. Determinants of COVID-19 vaccine-induced myocarditis. Ther. Adv. Drug Saf. 2024;15:20420986241226566. doi: 10.1177/20420986241226566.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/20420986241226566</ArticleId><ArticleId IdType="pmc">PMC10823859</ArticleId><ArticleId IdType="pubmed">38293564</ArticleId></ArticleIdList></Reference><Reference><Citation>Allas G.D.O., Arizala J.D.R., Manalo R.V.M. COVID-19 Adenoviral Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT), COVID-19-Related Thrombosis, and the Thrombotic Thrombocytopenic Syndromes. Hematol. Rep. 2022;14:358&#x2013;372. doi: 10.3390/hematolrep14040050.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/hematolrep14040050</ArticleId><ArticleId IdType="pmc">PMC9778187</ArticleId><ArticleId IdType="pubmed">36547234</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen W., Li Z., Yang B., Wang P., Zhou Q., Zhang Z., Zhu J., Chen X., Yang P., Zhou H. Delayed-phase thrombocytopenia in patients with coronavirus disease 2019 (COVID-19) Br. J. Haematol. 2020;190:179&#x2013;184. doi: 10.1111/bjh.16885.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bjh.16885</ArticleId><ArticleId IdType="pmc">PMC7283673</ArticleId><ArticleId IdType="pubmed">32453877</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y., Xu Z., Wang P., Li X.M., Shuai Z.W., Ye D.Q., Pan H.F. New-onset autoimmune phenomena post-COVID-19 vaccination. Immunology. 2022;165:386&#x2013;401. doi: 10.1111/imm.13443.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/imm.13443</ArticleId><ArticleId IdType="pubmed">34957554</ArticleId></ArticleIdList></Reference><Reference><Citation>Cines D.B., Greinacher A. Vaccine-induced immune thrombotic thrombocytopenia. Blood. 2023;141:1659&#x2013;1665. doi: 10.1182/blood.2022017696.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.2022017696</ArticleId><ArticleId IdType="pmc">PMC9870607</ArticleId><ArticleId IdType="pubmed">36669155</ArticleId></ArticleIdList></Reference><Reference><Citation>Danish F.I., Rabani A.E., Subhani F.E., Yasmin S., Koul S.S. COVID-19: Vaccine-induced immune thrombotic thrombocytopenia. Eur. J. Haematol. 2022;109:619&#x2013;632. doi: 10.1111/ejh.13855.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ejh.13855</ArticleId><ArticleId IdType="pmc">PMC9538855</ArticleId><ArticleId IdType="pubmed">36030503</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim A.Y., Woo W., Yon D.K., Lee S.W., Yang J.W., Kim J.H., Park S., Koyanagi A., Kim M.S., Lee S., et al. Thrombosis patterns and clinical outcome of COVID-19 vaccine-induced immune thrombotic thrombocytopenia: A Systematic Review and Meta-Analysis. Int. J. Infect. Dis. 2022;119:130&#x2013;139. doi: 10.1016/j.ijid.2022.03.034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2022.03.034</ArticleId><ArticleId IdType="pmc">PMC8942584</ArticleId><ArticleId IdType="pubmed">35339716</ArticleId></ArticleIdList></Reference><Reference><Citation>Swan D., Enright H., Desmond R., Le G., El Hassadi E., Hennessy B., Lynott F., O&#x2019;Keeffe D., Crowley M., Smyth L., et al. Vaccine-induced thrombosis and thrombocytopenia (VITT) in Ireland: A review of cases and current practices. Thromb. Update. 2021;5:100086. doi: 10.1016/j.tru.2021.100086.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tru.2021.100086</ArticleId><ArticleId IdType="pmc">PMC8578028</ArticleId><ArticleId IdType="pubmed">38620810</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong R.S., Wu A., To K.F., Lee N., Lam C.W., Wong C.K., Chan P.K., Ng M.H., Yu L.M., Hui D.S., et al. Haematological manifestations in patients with severe acute respiratory syndrome: Retrospective analysis. BMJ. 2003;326:1358&#x2013;1362. doi: 10.1136/bmj.326.7403.1358.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.326.7403.1358</ArticleId><ArticleId IdType="pmc">PMC162124</ArticleId><ArticleId IdType="pubmed">12816821</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y., Bissola A.L., Treverton J., Hack M., Lychacz M., Kwok S., Arnold A., Nazy I. Vaccine-Induced Immune Thrombotic Thrombocytopenia: Clinicopathologic Features and New Perspectives on Anti-PF4 Antibody-Mediated Disorders. J. Clin. Med. 2024;13:1012. doi: 10.3390/jcm13041012.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm13041012</ArticleId><ArticleId IdType="pmc">PMC10889051</ArticleId><ArticleId IdType="pubmed">38398325</ArticleId></ArticleIdList></Reference><Reference><Citation>Abara W.E., Gee J., Marquez P., Woo J., Myers T.R., DeSantis A., Baumblatt J.A.G., Woo E.J., Thompson D., Nair N., et al. Reports of Guillain-Barre Syndrome afterCOVID-19 Vaccination in the United States. JAMA Netw. Open. 2023;6:e2253845. doi: 10.1001/jamanetworkopen.2022.53845.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2022.53845</ArticleId><ArticleId IdType="pmc">PMC9892957</ArticleId><ArticleId IdType="pubmed">36723942</ArticleId></ArticleIdList></Reference><Reference><Citation>Abuawwad M.T., Taha M.J.J., Taha A.J., Kozaa Y.A., Falah O., Abuawwad I.T., Hammad E.M., Mahmoud A.A., Aladawi M., Serhan H.A. Guillain-Barre syndrome after COVID-19 vaccination: A systematic review and analysis of case reports. Clin. Neurol. Neurosurg. 2024;238:108183. doi: 10.1016/j.clineuro.2024.108183.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clineuro.2024.108183</ArticleId><ArticleId IdType="pubmed">38401232</ArticleId></ArticleIdList></Reference><Reference><Citation>Alijanzadeh D., Soltani A., Afra F., Salmanpour F., Loghman A.H., Samieefar N., Rezaei N. Clinical characteristics and prognosis of temporary miller fisher syndrome following COVID-19 vaccination: A systematic review of case studies. BMC Neurol. 2023;23:332. doi: 10.1186/s12883-023-03375-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12883-023-03375-4</ArticleId><ArticleId IdType="pmc">PMC10512542</ArticleId><ArticleId IdType="pubmed">37735648</ArticleId></ArticleIdList></Reference><Reference><Citation>Finsterer J. Neurological side effects of SARS-CoV-2 vaccinations. Acta Neurol. Scand. 2022;145:5&#x2013;9. doi: 10.1111/ane.13550.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ane.13550</ArticleId><ArticleId IdType="pmc">PMC8653194</ArticleId><ArticleId IdType="pubmed">34750810</ArticleId></ArticleIdList></Reference><Reference><Citation>Hadhiah K., Alhashim A., Al-Dandan H.A., Alhassan E., Alqarni A.M., Memish A.A.A., Alabdali M. Guillain-Barre syndrome post-SARS-CoV-2 vaccine: A systematic review and data analysis on its clinical, laboratory, electrophysiological, and radiological features. Front. Neurol. 2024;15:1332364. doi: 10.3389/fneur.2024.1332364.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2024.1332364</ArticleId><ArticleId IdType="pmc">PMC10863047</ArticleId><ArticleId IdType="pubmed">38352138</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogunjimi O.B., Tsalamandris G., Paladini A., Varrassi G., Zis P. Guillain-Barre Syndrome Induced by Vaccination against COVID-19: A Systematic Review and Meta-Analysis. Cureus. 2023;15:e37578. doi: 10.7759/cureus.37578.</Citation><ArticleIdList><ArticleId IdType="doi">10.7759/cureus.37578</ArticleId><ArticleId IdType="pmc">PMC10183219</ArticleId><ArticleId IdType="pubmed">37193456</ArticleId></ArticleIdList></Reference><Reference><Citation>Rzymski P. Guillain-Barre syndrome and COVID-19 vaccines: Focus on adenoviral vectors. Front. Immunol. 2023;14:1183258. doi: 10.3389/fimmu.2023.1183258.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2023.1183258</ArticleId><ArticleId IdType="pmc">PMC10169623</ArticleId><ArticleId IdType="pubmed">37180147</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu M., Nie S., Qiao Y., Ma Y. Guillain-Barre syndrome following COVID-19 vaccines: A review of literature. Front. Immunol. 2023;14:1078197. doi: 10.3389/fimmu.2023.1078197.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2023.1078197</ArticleId><ArticleId IdType="pmc">PMC9975597</ArticleId><ArticleId IdType="pubmed">36875094</ArticleId></ArticleIdList></Reference><Reference><Citation>Abicic A., Adamec I., Habek M. Miller Fisher syndrome following Pfizer COVID-19 vaccine. Neurol. Sci. 2022;43:1495&#x2013;1497. doi: 10.1007/s10072-021-05776-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10072-021-05776-0</ArticleId><ArticleId IdType="pmc">PMC8611397</ArticleId><ArticleId IdType="pubmed">34817727</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J.E., Yoon B.A., Kim Y.H., Kim J.K., Bae J.S. Miller Fisher syndrome following COVID-19 vaccines: A scoping review. Acta Neurol. Scand. 2022;146:604&#x2013;609. doi: 10.1111/ane.13687.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ane.13687</ArticleId><ArticleId IdType="pmc">PMC9539325</ArticleId><ArticleId IdType="pubmed">35938305</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang H., Cao Y., Zhong W., Ma Z., Liu J., Chen H. Miller-Fisher syndrome and Guillain-Barre syndrome overlap syndrome following inactivated COVID-19 vaccine: Case report and scope review. Hum. Vaccin. Immunother. 2022;18:2125753. doi: 10.1080/21645515.2022.2125753.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2022.2125753</ArticleId><ArticleId IdType="pmc">PMC9746535</ArticleId><ArticleId IdType="pubmed">36315834</ArticleId></ArticleIdList></Reference><Reference><Citation>Poyraz T. Miller Fisher Syndrome Associated With COVID-19: A History of Molecular Mimicry and an Up-to-Date Review of the Literature. Cureus. 2023;15:e43111. doi: 10.7759/cureus.43111.</Citation><ArticleIdList><ArticleId IdType="doi">10.7759/cureus.43111</ArticleId><ArticleId IdType="pmc">PMC10484161</ArticleId><ArticleId IdType="pubmed">37692684</ArticleId></ArticleIdList></Reference><Reference><Citation>Hehir M.K., 2nd, Li Y. Diagnosis and Management of Myasthenia Gravis. Continuum. 2022;28:1615&#x2013;1642. doi: 10.1212/CON.0000000000001161.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/CON.0000000000001161</ArticleId><ArticleId IdType="pubmed">36537972</ArticleId></ArticleIdList></Reference><Reference><Citation>Maher D.I., Hogarty D., Ben Artsi E. Acute onset ocular myasthenia gravis after vaccination with the Oxford-AstraZeneca COVID-19 vaccine. Orbit. 2023;42:630&#x2013;634. doi: 10.1080/01676830.2022.2062777.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/01676830.2022.2062777</ArticleId><ArticleId IdType="pubmed">35499172</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirmosayyeb O., Moases Ghaffary E., Mazdak M., Bagheri Z., Bagherieh S., Shaygannejad V. Is Myasthenia Gravis a Real Complication of the COVID-19 Vaccine? A Case Report-Based Systematic Review. Can. J. Infect. Dis. Med. Microbiol. 2022;2022:5009450. doi: 10.1155/2022/5009450.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2022/5009450</ArticleId><ArticleId IdType="pmc">PMC9509275</ArticleId><ArticleId IdType="pubmed">36164665</ArticleId></ArticleIdList></Reference><Reference><Citation>Tayebi A., Samimisedeh P., Jafari Afshar E., Mahmoudnia S., Milan N., Ayati A., Madady A., Rastad H. Neuromuscular diseases associated with COVID-19 vaccines: A systematic review and pooled analysis of 258 patients. BMC Neurol. 2023;23:437. doi: 10.1186/s12883-023-03486-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12883-023-03486-y</ArticleId><ArticleId IdType="pmc">PMC10712145</ArticleId><ArticleId IdType="pubmed">38082244</ArticleId></ArticleIdList></Reference><Reference><Citation>Tayebi A.H., Samimisedeh P., Jafari Afshar E., Ayati A., Ghalehnovi E., Foroutani L., Abbasi Khoshsirat N., Rastad H. Clinical features and outcomes of Myasthenia Gravis associated with COVID-19 vaccines: A systematic review and pooled analysis. Medicine. 2023;102:e34890. doi: 10.1097/MD.0000000000034890.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MD.0000000000034890</ArticleId><ArticleId IdType="pmc">PMC10553155</ArticleId><ArticleId IdType="pubmed">37800781</ArticleId></ArticleIdList></Reference><Reference><Citation>Virgilio E., Tondo G., Montabone C., Comi C. COVID-19 Vaccination and Late-Onset Myasthenia Gravis: A New Case Report and Review of the Literature. Int. J. Environ. Res. Public Health. 2022;20:467. doi: 10.3390/ijerph20010467.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijerph20010467</ArticleId><ArticleId IdType="pmc">PMC9819717</ArticleId><ArticleId IdType="pubmed">36612789</ArticleId></ArticleIdList></Reference><Reference><Citation>Ebrahimi N., Mazdak M., Shaygannejad V., Mirmosayyeb O. CNS demyelinating disease following inactivated or viral vector SARS-CoV-2 vaccines: A case series. Vaccine. 2023;41:1003&#x2013;1008. doi: 10.1016/j.vaccine.2023.01.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2023.01.003</ArticleId><ArticleId IdType="pmc">PMC9816077</ArticleId><ArticleId IdType="pubmed">36635139</ArticleId></ArticleIdList></Reference><Reference><Citation>Ismail I.I., Salama S. A systematic review of cases of CNS demyelination following COVID-19 vaccination. J. Neuroimmunol. 2022;362:577765. doi: 10.1016/j.jneuroim.2021.577765.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jneuroim.2021.577765</ArticleId><ArticleId IdType="pmc">PMC8577051</ArticleId><ArticleId IdType="pubmed">34839149</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim K.H., Kim S.H., Park N.Y., Hyun J.W., Kim H.J. Onset of various CNS inflammatory demyelination diseases following COVID-19 vaccinations. Mult. Scler. Relat. Disord. 2022;68:104141. doi: 10.1016/j.msard.2022.104141.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.msard.2022.104141</ArticleId><ArticleId IdType="pmc">PMC9392895</ArticleId><ArticleId IdType="pubmed">36037757</ArticleId></ArticleIdList></Reference><Reference><Citation>Netravathi M., Dhamija K., Gupta M., Tamborska A., Nalini A., Holla V.V., Nitish L.K., Menon D., Pal P.K., Seena V., et al. COVID-19 vaccine associated demyelination &amp; its association with MOG antibody. Mult. Scler. Relat. Disord. 2022;60:103739. doi: 10.1016/j.msard.2022.103739.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.msard.2022.103739</ArticleId><ArticleId IdType="pmc">PMC8917969</ArticleId><ArticleId IdType="pubmed">35306244</ArticleId></ArticleIdList></Reference><Reference><Citation>Rinaldi V., Bellucci G., Buscarinu M.C., Renie R., Marrone A., Nasello M., Zancan V., Nistri R., Palumbo R., Salerno A., et al. CNS inflammatory demyelinating events after COVID-19 vaccines: A case series and systematic review. Front. Neurol. 2022;13:1018785. doi: 10.3389/fneur.2022.1018785.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2022.1018785</ArticleId><ArticleId IdType="pmc">PMC9752005</ArticleId><ArticleId IdType="pubmed">36530641</ArticleId></ArticleIdList></Reference><Reference><Citation>Salunkhe M., Tayade K., Priyadarshi M., Goel V., Gulati I., Garg A., Bhatia R., Srivastava M.V.P. Spectrum of various CNS inflammatory demyelination diseases following COVID-19 vaccinations. Acta Neurol. Belg. 2024;124:193&#x2013;203. doi: 10.1007/s13760-023-02373-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13760-023-02373-0</ArticleId><ArticleId IdType="pubmed">37668946</ArticleId></ArticleIdList></Reference><Reference><Citation>Albakri K., Khaity A., Atwan H., Saleh O., Al-Hajali M., Cadri S., Diab R.A., Albazee E., Negida A. Bell&#x2019;s Palsy and COVID-19 Vaccines: A Systematic Review and Meta-Analysis. Vaccines. 2023;11:236. doi: 10.3390/vaccines11020236.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines11020236</ArticleId><ArticleId IdType="pmc">PMC9961047</ArticleId><ArticleId IdType="pubmed">36851114</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirillo N., Doan R. The association between COVID-19 vaccination and Bell&#x2019;s palsy. Lancet Infect. Dis. 2022;22:5&#x2013;6. doi: 10.1016/S1473-3099(21)00467-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(21)00467-9</ArticleId><ArticleId IdType="pmc">PMC8367190</ArticleId><ArticleId IdType="pubmed">34411533</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim S., Kang M., Park J.S., Seok H.Y. Risk and characteristics of Bell&#x2019;s palsy in adults as an adverse event following COVID-19 vaccination: A retrospective study. Acta Neurol. Belg. 2023;123:2185&#x2013;2193. doi: 10.1007/s13760-023-02245-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13760-023-02245-7</ArticleId><ArticleId IdType="pmc">PMC9924857</ArticleId><ArticleId IdType="pubmed">36781626</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdelhady M., Husain M.A., Hawas Y., Elazb M.A., Mansour L.S., Mohamed M., Abdelwahab M.M., Aljabali A., Negida A. Encephalitis following COVID-19 Vaccination: A Systematic Review. Vaccines. 2023;11:576. doi: 10.3390/vaccines11030576.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines11030576</ArticleId><ArticleId IdType="pmc">PMC10054808</ArticleId><ArticleId IdType="pubmed">36992160</ArticleId></ArticleIdList></Reference><Reference><Citation>Abu-Abaa M., Dawood G., Arshad H., Jumaah O., Landau D. A Possible Case of Autoimmune Encephalitis aftermRNA COVID-19 Booster Vaccine: A Case Report. Cureus. 2022;14:e31118. doi: 10.7759/cureus.31118.</Citation><ArticleIdList><ArticleId IdType="doi">10.7759/cureus.31118</ArticleId><ArticleId IdType="pmc">PMC9720496</ArticleId><ArticleId IdType="pubmed">36479395</ArticleId></ArticleIdList></Reference><Reference><Citation>Heming M., Li X., Rauber S., Mausberg A.K., Borsch A.L., Hartlehnert M., Singhal A., Lu I.N., Fleischer M., Szepanowski F., et al. Neurological Manifestations of COVID-19 Feature T Cell Exhaustion and Dedifferentiated Monocytes in Cerebrospinal Fluid. Immunity. 2021;54:164&#x2013;175 e166. doi: 10.1016/j.immuni.2020.12.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2020.12.011</ArticleId><ArticleId IdType="pmc">PMC7831653</ArticleId><ArticleId IdType="pubmed">33382973</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Y.F., Ho T.C., Chang C.C., Shen D.H., Chan H.P., Chuang K.P., Tyan Y.C., Yang M.H. A Rare Adverse Effect of the COVID-19 Vaccine on Autoimmune Encephalitis. Vaccines. 2022;10:1114. doi: 10.3390/vaccines10071114.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines10071114</ArticleId><ArticleId IdType="pmc">PMC9319671</ArticleId><ArticleId IdType="pubmed">35891278</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan E., Shrestha A.K., Colantonio M.A., Liberio R.N., Sriwastava S. Acute transverse myelitis following SARS-CoV-2 vaccination: A case report and review of literature. J. Neurol. 2022;269:1121&#x2013;1132. doi: 10.1007/s00415-021-10785-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-021-10785-2</ArticleId><ArticleId IdType="pmc">PMC8418691</ArticleId><ArticleId IdType="pubmed">34482455</ArticleId></ArticleIdList></Reference><Reference><Citation>Shin H.R., Kim B.K., Lee S.T., Kim A. Autoimmune Encephalitis as an Adverse Event of COVID-19 Vaccination. J. Clin. Neurol. 2022;18:114&#x2013;116. doi: 10.3988/jcn.2022.18.1.114.</Citation><ArticleIdList><ArticleId IdType="doi">10.3988/jcn.2022.18.1.114</ArticleId><ArticleId IdType="pmc">PMC8762504</ArticleId><ArticleId IdType="pubmed">35021289</ArticleId></ArticleIdList></Reference><Reference><Citation>Finsterer J. Small fiber neuropathy as a complication of SARS-CoV-2 vaccinations. J. Family Med. Prim. Care. 2022;11:4071&#x2013;4073. doi: 10.4103/jfmpc.jfmpc_2394_21.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/jfmpc.jfmpc_2394_21</ArticleId><ArticleId IdType="pmc">PMC9648331</ArticleId><ArticleId IdType="pubmed">36387712</ArticleId></ArticleIdList></Reference><Reference><Citation>Hertz D., Scorza F.A., Fiorini A.C., Finsterer J. SARS-CoV-2 vaccination complicated by small fiber neuropathy, mast cell activation syndrome, and pericarditis. Clinics. 2023;78:100304. doi: 10.1016/j.clinsp.2023.100304.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinsp.2023.100304</ArticleId><ArticleId IdType="pmc">PMC10681913</ArticleId><ArticleId IdType="pubmed">37956597</ArticleId></ArticleIdList></Reference><Reference><Citation>Mastropaolo M., Hasbani M.J. Small Fiber Neuropathy Triggered by COVID-19 Vaccination: Association with FGFR3 Autoantibodies and Improvement during Intravenous Immunoglobulin Treatment. Case Rep. Neurol. 2023;15:6&#x2013;10. doi: 10.1159/000528566.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000528566</ArticleId><ArticleId IdType="pmc">PMC9891845</ArticleId><ArticleId IdType="pubmed">36742446</ArticleId></ArticleIdList></Reference><Reference><Citation>Waheed W., Carey M.E., Tandan S.R., Tandan R. Post COVID-19 vaccine small fiber neuropathy. Muscle Nerve. 2021;64:E1&#x2013;E2. doi: 10.1002/mus.27251.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.27251</ArticleId><ArticleId IdType="pmc">PMC8250971</ArticleId><ArticleId IdType="pubmed">33851437</ArticleId></ArticleIdList></Reference><Reference><Citation>Balasubramanian I., Faheem A., Padhy S.K., Menon V. Psychiatric adverse reactions to COVID-19 vaccines: A rapid review of published case reports. Asian J. Psychiatr. 2022;71:103129. doi: 10.1016/j.ajp.2022.103129.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajp.2022.103129</ArticleId><ArticleId IdType="pmc">PMC9006421</ArticleId><ArticleId IdType="pubmed">35447503</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim H.J., Kim M.H., Choi M.G., Chun E.M. Psychiatric adverse events following COVID-19 vaccination: A population-based cohort study in Seoul, South Korea. Mol. Psychiatry. 2024 doi: 10.1038/s41380-024-02627-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41380-024-02627-0</ArticleId><ArticleId IdType="pubmed">38834668</ArticleId></ArticleIdList></Reference><Reference><Citation>Lazareva M., Renemane L., Vrublevska J., Rancans E. New-onset psychosis following COVID-19 vaccination: A systematic review. Front. Psychiatry. 2024;15:1360338. doi: 10.3389/fpsyt.2024.1360338.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpsyt.2024.1360338</ArticleId><ArticleId IdType="pmc">PMC11046000</ArticleId><ArticleId IdType="pubmed">38680784</ArticleId></ArticleIdList></Reference><Reference><Citation>Lien Y.L., Wei C.Y., Liang J.S. Acute psychosis induced by mRNA-based COVID-19 vaccine in adolescents: A pediatric case report. Pediatr. Neonatol. 2023;64:364&#x2013;365. doi: 10.1016/j.pedneo.2022.10.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pedneo.2022.10.007</ArticleId><ArticleId IdType="pmc">PMC9803367</ArticleId><ArticleId IdType="pubmed">36641359</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO  Adverse Events following Immunization.  [(accessed on 15 September 2024)].  Available online:  https://www.who.int/groups/global-advisory-committee-on-vaccine-safety/topics/aefi/aefi.</Citation></Reference><Reference><Citation>Shoenfeld Y., Aron-Maor A. Vaccination and autoimmunity-v&#x2019;accinosis&#x2019;: A dangerous liaison? J. Autoimmun. 2000;14:1&#x2013;10. doi: 10.1006/jaut.1999.0346.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/jaut.1999.0346</ArticleId><ArticleId IdType="pubmed">10648110</ArticleId></ArticleIdList></Reference><Reference><Citation>Salemi S., D&#x2019;Amelio R. Could autoimmunity be induced by vaccination? Int. Rev. Immunol. 2010;29:247&#x2013;269. doi: 10.3109/08830181003746304.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/08830181003746304</ArticleId><ArticleId IdType="pubmed">20521925</ArticleId></ArticleIdList></Reference><Reference><Citation>Pulendran B., Ahmed R. Immunological mechanisms of vaccination. Nat. Immunol. 2011;12:509&#x2013;517. doi: 10.1038/ni.2039.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni.2039</ArticleId><ArticleId IdType="pmc">PMC3253344</ArticleId><ArticleId IdType="pubmed">21739679</ArticleId></ArticleIdList></Reference><Reference><Citation>Castellino F., Galli G., Del Giudice G., Rappuoli R. Generating memory with vaccination. Eur. J. Immunol. 2009;39:2100&#x2013;2105. doi: 10.1002/eji.200939550.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/eji.200939550</ArticleId><ArticleId IdType="pubmed">19637203</ArticleId></ArticleIdList></Reference><Reference><Citation>Safary A., Akbarzadeh-Khiavi M., Barar J., Omidi Y. SARS-CoV-2 vaccine-triggered autoimmunity: Molecular mimicry and/or bystander activation of the immune system. Bioimpacts. 2023;13:269&#x2013;273. doi: 10.34172/bi.2023.27494.</Citation><ArticleIdList><ArticleId IdType="doi">10.34172/bi.2023.27494</ArticleId><ArticleId IdType="pmc">PMC10460773</ArticleId><ArticleId IdType="pubmed">37645029</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujinami R.S., von Herrath M.G., Christen U., Whitton J.L. Molecular mimicry, bystander activation, or viral persistence: Infections and autoimmune disease. Clin. Microbiol. Rev. 2006;19:80&#x2013;94. doi: 10.1128/CMR.19.1.80-94.2006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/CMR.19.1.80-94.2006</ArticleId><ArticleId IdType="pmc">PMC1360274</ArticleId><ArticleId IdType="pubmed">16418524</ArticleId></ArticleIdList></Reference><Reference><Citation>Talotta R. Do COVID-19 RNA-based vaccines put at risk of immune-mediated diseases? In reply to &#x201c;potential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases&#x201d;. Clin. Immunol. 2021;224:108665. doi: 10.1016/j.clim.2021.108665.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clim.2021.108665</ArticleId><ArticleId IdType="pmc">PMC7833091</ArticleId><ArticleId IdType="pubmed">33429060</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo M., Liu X., Chen X., Li Q. Insights into new-onset autoimmune diseases after COVID-19 vaccination. Autoimmun. Rev. 2023;22:103340. doi: 10.1016/j.autrev.2023.103340.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2023.103340</ArticleId><ArticleId IdType="pmc">PMC10108562</ArticleId><ArticleId IdType="pubmed">37075917</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanuri S.H., Sirrkay P.J. Adjuvants in COVID-19 vaccines: Innocent bystanders or culpable abettors for stirring up COVID-heart syndrome. Ther. Adv. Vaccines Immunother. 2024;12:25151355241228439. doi: 10.1177/25151355241228439.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/25151355241228439</ArticleId><ArticleId IdType="pmc">PMC10846003</ArticleId><ArticleId IdType="pubmed">38322819</ArticleId></ArticleIdList></Reference><Reference><Citation>Vanderlugt C.L., Miller S.D. Epitope spreading in immune-mediated diseases: Implications for immunotherapy. Nat. Rev. Immunol. 2002;2:85&#x2013;95. doi: 10.1038/nri724.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri724</ArticleId><ArticleId IdType="pubmed">11910899</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy W.J., Longo D.L. A Possible Role for Anti-idiotype Antibodies in SARS-CoV-2 Infection and Vaccination. N. Engl. J. Med. 2022;386:394&#x2013;396. doi: 10.1056/NEJMcibr2113694.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMcibr2113694</ArticleId><ArticleId IdType="pubmed">34818473</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikewaki N., Kurosawa G., Levy G.A., Preethy S., Abraham S.J.K. Antibody dependent disease enhancement (ADE) after COVID-19 vaccination and beta glucans as a safer strategy in management. Vaccine. 2023;41:2427&#x2013;2429. doi: 10.1016/j.vaccine.2023.03.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2023.03.005</ArticleId><ArticleId IdType="pmc">PMC9992059</ArticleId><ArticleId IdType="pubmed">36906407</ArticleId></ArticleIdList></Reference><Reference><Citation>Sawant J., Patil A., Kurle S. A Review: Understanding Molecular Mechanisms of Antibody-Dependent Enhancement in Viral Infections. Vaccines. 2023;11:1240. doi: 10.3390/vaccines11071240.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines11071240</ArticleId><ArticleId IdType="pmc">PMC10384352</ArticleId><ArticleId IdType="pubmed">37515055</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulrich H., Pillat M.M., Tarnok A. Dengue Fever, COVID-19 (SARS-CoV-2), and Antibody-Dependent Enhancement (ADE): A Perspective. Cytom. A. 2020;97:662&#x2013;667. doi: 10.1002/cyto.a.24047.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cyto.a.24047</ArticleId><ArticleId IdType="pmc">PMC7300451</ArticleId><ArticleId IdType="pubmed">32506725</ArticleId></ArticleIdList></Reference><Reference><Citation>Sachinidis A., Garyfallos A. COVID-19 vaccination can occasionally trigger autoimmune phenomena, probably via inducing age-associated B cells. Int. J. Rheum. Dis. 2022;25:83&#x2013;85. doi: 10.1111/1756-185X.14238.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1756-185X.14238</ArticleId><ArticleId IdType="pmc">PMC8652459</ArticleId><ArticleId IdType="pubmed">34766739</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao T., Cai Y., Jiang Y., He X., Wei Y., Yu Y., Tian X. Vaccine adjuvants: Mechanisms and platforms. Signal Transduct. Target. Ther. 2023;8:283. doi: 10.1038/s41392-023-01557-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-023-01557-7</ArticleId><ArticleId IdType="pmc">PMC10356842</ArticleId><ArticleId IdType="pubmed">37468460</ArticleId></ArticleIdList></Reference><Reference><Citation>Trougakos I.P., Terpos E., Alexopoulos H., Politou M., Paraskevis D., Scorilas A., Kastritis E., Andreakos E., Dimopoulos M.A. Adverse effects of COVID-19 mRNA vaccines: The spike hypothesis. Trends Mol. Med. 2022;28:542&#x2013;554. doi: 10.1016/j.molmed.2022.04.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molmed.2022.04.007</ArticleId><ArticleId IdType="pmc">PMC9021367</ArticleId><ArticleId IdType="pubmed">35537987</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L., More K.R., Ojha A., Jackson C.B., Quinlan B.D., Li H., He W., Farzan M., Pardi N., Choe H. Effect of mRNA-LNP components of two globally-marketed COVID-19 vaccines on efficacy and stability. NPJ Vaccines. 2023;8:156. doi: 10.1038/s41541-023-00751-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41541-023-00751-6</ArticleId><ArticleId IdType="pmc">PMC10567765</ArticleId><ArticleId IdType="pubmed">37821446</ArticleId></ArticleIdList></Reference><Reference><Citation>Gutman E.G., Fernandes R.A., Raposo-Vedovi J.V., Salvio A.L., Duarte L.A., Tardim C.F., Costa V.G.C., Pereira V., Bahia P.R.V., da Silva M.M., et al. Molecular Mimicry between SARS-CoV-2 Proteins and Human Self-Antigens Related with Autoimmune Central Nervous System (CNS) Disorders. Microorganisms. 2023;11:2902. doi: 10.3390/microorganisms11122902.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/microorganisms11122902</ArticleId><ArticleId IdType="pmc">PMC10745528</ArticleId><ArticleId IdType="pubmed">38138047</ArticleId></ArticleIdList></Reference><Reference><Citation>Nunez-Castilla J., Stebliankin V., Baral P., Balbin C.A., Sobhan M., Cickovski T., Mondal A.M., Narasimhan G., Chapagain P., Mathee K., et al. Potential Autoimmunity Resulting from Molecular Mimicry between SARS-CoV-2 Spike and Human Proteins. Viruses. 2022;14:1415. doi: 10.3390/v14071415.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v14071415</ArticleId><ArticleId IdType="pmc">PMC9318917</ArticleId><ArticleId IdType="pubmed">35891400</ArticleId></ArticleIdList></Reference><Reference><Citation>Rojas M., Herran M., Ramirez-Santana C., Leung P.S.C., Anaya J.M., Ridgway W.M., Gershwin M.E. Molecular mimicry and autoimmunity in the time of COVID-19. J. Autoimmun. 2023;139:103070. doi: 10.1016/j.jaut.2023.103070.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2023.103070</ArticleId><ArticleId IdType="pmc">PMC10258587</ArticleId><ArticleId IdType="pubmed">37390745</ArticleId></ArticleIdList></Reference><Reference><Citation>Sprent J., King C. COVID-19 vaccine side effects: The positives about feeling bad. Sci. Immunol. 2021;6:eabj9256. doi: 10.1126/sciimmunol.abj9256.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.abj9256</ArticleId><ArticleId IdType="pmc">PMC9267253</ArticleId><ArticleId IdType="pubmed">34158390</ArticleId></ArticleIdList></Reference><Reference><Citation>Greinacher A., Langer F., Makris M., Pai M., Pavord S., Tran H., Warkentin T.E. Vaccine-induced immune thrombotic thrombocytopenia (VITT): Update on diagnosis and management considering different resources. J. Thromb. Haemost. 2022;20:149&#x2013;156. doi: 10.1111/jth.15572.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.15572</ArticleId><ArticleId IdType="pmc">PMC8646430</ArticleId><ArticleId IdType="pubmed">34693641</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Z., Guo J., Bi L. Role of the NLRP3 inflammasome in autoimmune diseases. Biomed. Pharmacother. 2020;130:110542. doi: 10.1016/j.biopha.2020.110542.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopha.2020.110542</ArticleId><ArticleId IdType="pubmed">32738636</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen H.H., Yang Y.X., Meng X., Luo X.Y., Li X.M., Shuai Z.W., Ye D.Q., Pan H.F. NLRP3: A promising therapeutic target for autoimmune diseases. Autoimmun. Rev. 2018;17:694&#x2013;702. doi: 10.1016/j.autrev.2018.01.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2018.01.020</ArticleId><ArticleId IdType="pubmed">29729449</ArticleId></ArticleIdList></Reference><Reference><Citation>Boopathi V., Nahar J., Murugesan M., Subramaniyam S., Kong B.M., Choi S.K., Lee C.S., Ling L., Yang D.U., Yang D.C., et al. In silico and in vitro inhibition of host-based viral entry targets and cytokine storm in COVID-19 by ginsenoside compound K. Heliyon. 2023;9:e19341. doi: 10.1016/j.heliyon.2023.e19341.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.heliyon.2023.e19341</ArticleId><ArticleId IdType="pmc">PMC10558348</ArticleId><ArticleId IdType="pubmed">37809955</ArticleId></ArticleIdList></Reference><Reference><Citation>Landolina N., Ricci B., Veneziani I., Alicata C., Mariotti F.R., Pelosi A., Quatrini L., Mortari E.P., Carsetti R., Vacca P., et al. TLR2/4 are novel activating receptors for SARS-CoV-2 spike protein on NK cells. Front. Immunol. 2024;15:1368946. doi: 10.3389/fimmu.2024.1368946.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2024.1368946</ArticleId><ArticleId IdType="pmc">PMC11176535</ArticleId><ArticleId IdType="pubmed">38881905</ArticleId></ArticleIdList></Reference><Reference><Citation>du Preez H.N., Lin J., Maguire G.E.M., Aldous C., Kruger H.G. COVID-19 vaccine adverse events: Evaluating the pathophysiology with an emphasis on sulfur metabolism and endotheliopathy. Eur. J. Clin. Investig. 2024;2014:e14296. doi: 10.1111/eci.14296.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/eci.14296</ArticleId><ArticleId IdType="pubmed">39118373</ArticleId></ArticleIdList></Reference><Reference><Citation>Hajjo R., Sabbah D.A., Bardaweel S.K., Tropsha A. Shedding the Light on Post-Vaccine Myocarditis and Pericarditis in COVID-19 and Non-COVID-19 Vaccine Recipients. Vaccines. 2021;9:1186. doi: 10.3390/vaccines9101186.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines9101186</ArticleId><ArticleId IdType="pmc">PMC8541143</ArticleId><ArticleId IdType="pubmed">34696294</ArticleId></ArticleIdList></Reference><Reference><Citation>Rout A., Suri S., Vorla M., Kalra D.K. Myocarditis associated with COVID-19 and its vaccines&#x2014;A systematic review. Prog. Cardiovasc. Dis. 2022;74:111&#x2013;121. doi: 10.1016/j.pcad.2022.10.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pcad.2022.10.004</ArticleId><ArticleId IdType="pmc">PMC9596182</ArticleId><ArticleId IdType="pubmed">36279947</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel H., Sintou A., Chowdhury R.A., Rothery S., Iacob A.O., Prasad S., Rainer P.P., Martinon-Torres F., Sancho-Shimizu V., Shimizu C., et al. Evaluation of Autoantibody Binding to Cardiac Tissue in Multisystem Inflammatory Syndrome in Children and COVID-19 Vaccination-Induced Myocarditis. JAMA Netw. Open. 2023;6:e2314291. doi: 10.1001/jamanetworkopen.2023.14291.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2023.14291</ArticleId><ArticleId IdType="pmc">PMC10196878</ArticleId><ArticleId IdType="pubmed">37200028</ArticleId></ArticleIdList></Reference><Reference><Citation>Heidecker B., Dagan N., Balicer R., Eriksson U., Rosano G., Coats A., Tschope C., Kelle S., Poland G.A., Frustaci A., et al. Myocarditis following COVID-19 vaccine: Incidence, presentation, diagnosis, pathophysiology, therapy, and outcomes put into perspective. A clinical consensus document supported by the Heart Failure Association of the European Society of Cardiology (ESC) and the ESC Working Group on Myocardial and Pericardial Diseases. Eur. J. Heart Fail. 2022;24:2000&#x2013;2018. doi: 10.1002/ejhf.2669.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ejhf.2669</ArticleId><ArticleId IdType="pmc">PMC9538893</ArticleId><ArticleId IdType="pubmed">36065751</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaiswal V., Mukherjee D., Peng Ang S., Kainth T., Naz S., Babu Shrestha A., Agrawal V., Mitra S., Ee Chia J., Jilma B., et al. COVID-19 vaccine-associated myocarditis: Analysis of the suspected cases reported to the EudraVigilance and a systematic review of the published literature. Int. J. Cardiol. Heart Vasc. 2023;49:101280. doi: 10.1016/j.ijcha.2023.101280.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijcha.2023.101280</ArticleId><ArticleId IdType="pmc">PMC10746454</ArticleId><ArticleId IdType="pubmed">38143781</ArticleId></ArticleIdList></Reference><Reference><Citation>Pillay J., Gaudet L., Wingert A., Bialy L., Mackie A.S., Paterson D.I., Hartling L. Incidence, risk factors, natural history, and hypothesised mechanisms of myocarditis and pericarditis following COVID-19 vaccination: Living evidence syntheses and review. BMJ. 2022;378:e069445. doi: 10.1136/bmj-2021-069445.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj-2021-069445</ArticleId><ArticleId IdType="pmc">PMC9277081</ArticleId><ArticleId IdType="pubmed">35830976</ArticleId></ArticleIdList></Reference><Reference><Citation>Diaz G.A., Parsons G.T., Gering S.K., Meier A.R., Hutchinson I.V., Robicsek A. Myocarditis and Pericarditis afterVaccination for COVID-19. JAMA. 2021;326:1210&#x2013;1212. doi: 10.1001/jama.2021.13443.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2021.13443</ArticleId><ArticleId IdType="pmc">PMC8340007</ArticleId><ArticleId IdType="pubmed">34347001</ArticleId></ArticleIdList></Reference><Reference><Citation>McDonald M.A., Kafil T.S., Khoury M., Luk A.C., Wright M.K., Hawkins N.M. Myocarditis and Pericarditis aftermRNA COVID-19 Vaccination: 2024 Status and Management Update. Can. J. Cardiol. 2024;40:1536&#x2013;1540. doi: 10.1016/j.cjca.2024.03.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cjca.2024.03.016</ArticleId><ArticleId IdType="pubmed">38537672</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamath S., Gomah M.T., Stepman G., DiMartino P., Adetula I. COVID-19-Associated Acute Myocarditis: Risk Factors, Clinical Outcomes, and Implications for Early Detection and Management. Cureus. 2023;15:e44617. doi: 10.7759/cureus.44617.</Citation><ArticleIdList><ArticleId IdType="doi">10.7759/cureus.44617</ArticleId><ArticleId IdType="pmc">PMC10547603</ArticleId><ArticleId IdType="pubmed">37799242</ArticleId></ArticleIdList></Reference><Reference><Citation>Keshavarz P., Yazdanpanah F., Emad M., Hajati A., Nejati S.F., Ebrahimian Sadabad F., Azrumelashvili T., Mizandari M., Raman S.S. Myocarditis Following COVID-19 Vaccination: Cardiac Imaging Findings in 118 Studies. Tomography. 2022;8:1959&#x2013;1973. doi: 10.3390/tomography8040164.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/tomography8040164</ArticleId><ArticleId IdType="pmc">PMC9416085</ArticleId><ArticleId IdType="pubmed">36006062</ArticleId></ArticleIdList></Reference><Reference><Citation>Puchalski M., Kaminska H., Bartoszek M., Brzewski M., Werner B. COVID-19-Vaccination-Induced Myocarditis in Teenagers: Case Series with Further Follow-Up. Int. J. Environ. Res. Public Health. 2022;19:3456. doi: 10.3390/ijerph19063456.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijerph19063456</ArticleId><ArticleId IdType="pmc">PMC8954790</ArticleId><ArticleId IdType="pubmed">35329143</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanchez Tijmes F., Marschner C.A., de Matos J., Urzua Fresno C.M., Gutierrez Chacoff J.M., Thavendiranathan P., Fuss C., Hanneman K. Imaging Acute and Chronic Cardiac Complications of COVID-19 and after COVID-19 Vaccination. Radiographics. 2023;43:e230044. doi: 10.1148/rg.230044.</Citation><ArticleIdList><ArticleId IdType="doi">10.1148/rg.230044</ArticleId><ArticleId IdType="pubmed">37616171</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeo S.Z.J., Ho C.L. COVID-19 mRNA vaccine-related myocarditis: A PRISMA systematic review, imaging approach and differential diagnoses. Radiol. Case Rep. 2024;19:1008&#x2013;1019. doi: 10.1016/j.radcr.2023.11.070.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.radcr.2023.11.070</ArticleId><ArticleId IdType="pmc">PMC10788373</ArticleId><ArticleId IdType="pubmed">38226053</ArticleId></ArticleIdList></Reference><Reference><Citation>Guan W.J., Ni Z.Y., Hu Y., Liang W.H., Ou C.Q., He J.X., Liu L., Shan H., Lei C.L., Hui D.S.C., et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N. Engl. J. Med. 2020;382:1708&#x2013;1720. doi: 10.1056/NEJMoa2002032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2002032</ArticleId><ArticleId IdType="pmc">PMC7092819</ArticleId><ArticleId IdType="pubmed">32109013</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsang K.W., Ho P.L., Ooi G.C., Yee W.K., Wang T., Chan-Yeung M., Lam W.K., Seto W.H., Yam L.Y., Cheung T.M., et al. A cluster of cases of severe acute respiratory syndrome in Hong Kong. N. Engl. J. Med. 2003;348:1977&#x2013;1985. doi: 10.1056/NEJMoa030666.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa030666</ArticleId><ArticleId IdType="pubmed">12671062</ArticleId></ArticleIdList></Reference><Reference><Citation>Suhaimi S., Zaki I.A.H., Noordin Z.M., Hussin N.S.M., Ming L.C., Zulkifly H.H. COVID-19 vaccine-induced immune thrombotic thrombocytopenia: A review. Clin. Exp. Vaccine Res. 2023;12:265&#x2013;290. doi: 10.7774/cevr.2023.12.4.265.</Citation><ArticleIdList><ArticleId IdType="doi">10.7774/cevr.2023.12.4.265</ArticleId><ArticleId IdType="pmc">PMC10655150</ArticleId><ArticleId IdType="pubmed">38025914</ArticleId></ArticleIdList></Reference><Reference><Citation>Long B., Bridwell R., Gottlieb M. Thrombosis with thrombocytopenia syndrome associated with COVID-19 vaccines. Am. J. Emerg. Med. 2021;49:58&#x2013;61. doi: 10.1016/j.ajem.2021.05.054.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajem.2021.05.054</ArticleId><ArticleId IdType="pmc">PMC8143907</ArticleId><ArticleId IdType="pubmed">34062319</ArticleId></ArticleIdList></Reference><Reference><Citation>Meier R.T., Porcelijn L., Hofstede-van Egmond S., Henskens Y.M.C., Coutinho J.M., Kruip M., Stroobants A.K., Zwaginga J.J., van der Bom J.G., van der Schoot C.E., et al. Laboratory approach for vaccine-induced thrombotic thrombocytopenia diagnosis in the Netherlands. Vox Sang. 2024;119:728&#x2013;736. doi: 10.1111/vox.13633.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/vox.13633</ArticleId><ArticleId IdType="pubmed">38597072</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharifian-Dorche M., Bahmanyar M., Sharifian-Dorche A., Mohammadi P., Nomovi M., Mowla A. Vaccine-induced immune thrombotic thrombocytopenia and cerebral venous sinus thrombosis post COVID-19 vaccination; a systematic review. J. Neurol. Sci. 2021;428:117607. doi: 10.1016/j.jns.2021.117607.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2021.117607</ArticleId><ArticleId IdType="pmc">PMC8330139</ArticleId><ArticleId IdType="pubmed">34365148</ArticleId></ArticleIdList></Reference><Reference><Citation>Maramattom B.V., Lotlikar R.S., Sukumaran S. Central nervous system adverse events after ChAdOx1 vaccination. Neurol. Sci. 2022;43:3503&#x2013;3507. doi: 10.1007/s10072-022-06000-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10072-022-06000-3</ArticleId><ArticleId IdType="pmc">PMC8913322</ArticleId><ArticleId IdType="pubmed">35275317</ArticleId></ArticleIdList></Reference><Reference><Citation>Kakovan M., Ghorbani Shirkouhi S., Zarei M., Andalib S. Stroke Associated with COVID-19 Vaccines. J. Stroke Cerebrovasc. Dis. 2022;31:106440. doi: 10.1016/j.jstrokecerebrovasdis.2022.106440.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jstrokecerebrovasdis.2022.106440</ArticleId><ArticleId IdType="pmc">PMC8894799</ArticleId><ArticleId IdType="pubmed">35339857</ArticleId></ArticleIdList></Reference><Reference><Citation>Marcucci R., Marietta M. Vaccine-induced thrombotic thrombocytopenia: The elusive link between thrombosis and adenovirus-based SARS-CoV-2 vaccines. Intern. Emerg. Med. 2021;16:1113&#x2013;1119. doi: 10.1007/s11739-021-02793-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11739-021-02793-x</ArticleId><ArticleId IdType="pmc">PMC8243058</ArticleId><ArticleId IdType="pubmed">34191218</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma S.S., Gulli G., Sharma P. Cerebral venous sinus thrombosis following ChAdOx1 nCoV-19 AstraZeneca COVID-19 vaccine. JRSM Cardiovasc. Dis. 2023;12:20480040231169464. doi: 10.1177/20480040231169464.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/20480040231169464</ArticleId><ArticleId IdType="pmc">PMC10107960</ArticleId><ArticleId IdType="pubmed">37077469</ArticleId></ArticleIdList></Reference><Reference><Citation>Abbasi S., Alsermani A., Alsegayyir A., Altahan T., Alsermani M., Almustanyir S. Vaccine-Induced Thrombotic Thrombocytopenia: A Case of Splanchnic Veins Thrombosis. Cureus. 2022;14:e23507. doi: 10.7759/cureus.23507.</Citation><ArticleIdList><ArticleId IdType="doi">10.7759/cureus.23507</ArticleId><ArticleId IdType="pmc">PMC9038581</ArticleId><ArticleId IdType="pubmed">35494984</ArticleId></ArticleIdList></Reference><Reference><Citation>Botton J., Jabagi M.J., Bertrand M., Baricault B., Drouin J., Le Vu S., Weill A., Farrington P., Zureik M., Dray-Spira R. Risk for Myocardial Infarction, Stroke, and Pulmonary Embolism Following COVID-19 Vaccines in Adults Younger Than 75 Years in France. Ann. Intern. Med. 2022;175:1250&#x2013;1257. doi: 10.7326/M22-0988.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M22-0988</ArticleId><ArticleId IdType="pmc">PMC9425709</ArticleId><ArticleId IdType="pubmed">35994748</ArticleId></ArticleIdList></Reference><Reference><Citation>Elkoumy M., Schoen J., Loew A. Management of a severe bilateral pulmonary embolism as a complication of VITT following vaccination with AstraZeneca COVID-19 vaccine. BMJ Case Rep. 2022;15:e246770. doi: 10.1136/bcr-2021-246770.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bcr-2021-246770</ArticleId><ArticleId IdType="pmc">PMC9096475</ArticleId><ArticleId IdType="pubmed">35545306</ArticleId></ArticleIdList></Reference><Reference><Citation>Franchini M., Liumbruno G.M., Pezzo M. COVID-19 vaccine-associated immune thrombosis and thrombocytopenia (VITT): Diagnostic and therapeutic recommendations for a new syndrome. Eur. J. Haematol. 2021;107:173&#x2013;180. doi: 10.1111/ejh.13665.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ejh.13665</ArticleId><ArticleId IdType="pmc">PMC8239516</ArticleId><ArticleId IdType="pubmed">33987882</ArticleId></ArticleIdList></Reference><Reference><Citation>Favaloro E.J. Laboratory testing for suspected COVID-19 vaccine-induced (immune) thrombotic thrombocytopenia. Int. J. Lab. Hematol. 2021;43:559&#x2013;570. doi: 10.1111/ijlh.13629.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ijlh.13629</ArticleId><ArticleId IdType="pmc">PMC8444734</ArticleId><ArticleId IdType="pubmed">34138513</ArticleId></ArticleIdList></Reference><Reference><Citation>Rizk J.G., Gupta A., Sardar P., Henry B.M., Lewin J.C., Lippi G., Lavie C.J. Clinical Characteristics and Pharmacological Management of COVID-19 Vaccine-Induced Immune Thrombotic Thrombocytopenia With Cerebral Venous Sinus Thrombosis: A Review. JAMA Cardiol. 2021;6:1451&#x2013;1460. doi: 10.1001/jamacardio.2021.3444.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamacardio.2021.3444</ArticleId><ArticleId IdType="pubmed">34374713</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindhoff-Last E., Schonborn L., Zaninetti C., Warkentin T.E., Greinacher A. Rescue Therapy in Chronic Prothrombotic Autoimmune Anti-PF4 Disorder. N. Engl. J. Med. 2023;389:1339&#x2013;1341. doi: 10.1056/NEJMc2309016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2309016</ArticleId><ArticleId IdType="pubmed">37792621</ArticleId></ArticleIdList></Reference><Reference><Citation>Panagiota V., Dobbelstein C., Werwitzke S., Ganser A., Cooper N., Sachs U.J., Tiede A. Long-Term Outcomes after Vaccine-Induced Thrombotic Thrombocytopenia. Viruses. 2022;14:1702. doi: 10.3390/v14081702.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v14081702</ArticleId><ArticleId IdType="pmc">PMC9415056</ArticleId><ArticleId IdType="pubmed">36016324</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith C.W., Montague S.J., Kardeby C., Di Y., Lowe G.C., Lester W.A., Watson S.P., Nicolson P.L.R. Antiplatelet drugs block platelet activation by VITT patient serum. Blood. 2021;138:2733&#x2013;2740. doi: 10.1182/blood.2021012277.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.2021012277</ArticleId><ArticleId IdType="pmc">PMC8697531</ArticleId><ArticleId IdType="pubmed">34375398</ArticleId></ArticleIdList></Reference><Reference><Citation>Misra S., Kolappa K., Prasad M., Radhakrishnan D., Thakur K.T., Solomon T., Michael B.D., Winkler A.S., Beghi E., Guekht A., et al. Frequency of Neurologic Manifestations in COVID-19: A Systematic Review and Meta-analysis. Neurology. 2021;97:e2269&#x2013;e2281. doi: 10.1212/WNL.0000000000012930.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000012930</ArticleId><ArticleId IdType="pmc">PMC8665434</ArticleId><ArticleId IdType="pubmed">34635561</ArticleId></ArticleIdList></Reference><Reference><Citation>Etter M.M., Martins T.A., Kulsvehagen L., Possnecker E., Duchemin W., Hogan S., Sanabria-Diaz G., Muller J., Chiappini A., Rychen J., et al. Severe Neuro-COVID is associated with peripheral immune signatures, autoimmunity and neurodegeneration: A prospective cross-sectional study. Nat. Commun. 2022;13:6777. doi: 10.1038/s41467-022-34068-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-34068-0</ArticleId><ArticleId IdType="pmc">PMC9645766</ArticleId><ArticleId IdType="pubmed">36351919</ArticleId></ArticleIdList></Reference><Reference><Citation>Mundorf A.K., Semmler A., Heidecke H., Schott M., Steffen F., Bittner S., Lackner K.J., Schulze-Bosse K., Pawlitzki M., Meuth S.G., et al. Clinical and Diagnostic Features of Post-Acute COVID-19 Vaccination Syndrome (PACVS) Vaccines. 2024;12:790. doi: 10.3390/vaccines12070790.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines12070790</ArticleId><ArticleId IdType="pmc">PMC11281408</ArticleId><ArticleId IdType="pubmed">39066428</ArticleId></ArticleIdList></Reference><Reference><Citation>Querol L., Lleixa C. Novel Immunological and Therapeutic Insights in Guillain-Barre Syndrome and CIDP. Neurotherapeutics. 2021;18:2222&#x2013;2235. doi: 10.1007/s13311-021-01117-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13311-021-01117-3</ArticleId><ArticleId IdType="pmc">PMC8455117</ArticleId><ArticleId IdType="pubmed">34549385</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Vu S., Bertrand M., Botton J., Jabagi M.J., Drouin J., Semenzato L., Weill A., Dray-Spira R., Zureik M. Risk of Guillain-Barre Syndrome Following COVID-19 Vaccines: A Nationwide Self-Controlled Case Series Study. Neurology. 2023;101:e2094&#x2013;e2102. doi: 10.1212/WNL.0000000000207847.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000207847</ArticleId><ArticleId IdType="pmc">PMC10663040</ArticleId><ArticleId IdType="pubmed">37788935</ArticleId></ArticleIdList></Reference><Reference><Citation>Sah B.K., Fatima Z., Sah R.K., Syed B., Garg T., Chowdhury S., Ghosh B., Kunwar B., Shree A., Sah V.K., et al. Guillain-Barre syndrome following COVID-19 vaccination: A study of 70 case reports. Ann. Med. Surg. 2024;86:2067&#x2013;2080. doi: 10.1097/MS9.0000000000001915.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MS9.0000000000001915</ArticleId><ArticleId IdType="pmc">PMC10990410</ArticleId><ArticleId IdType="pubmed">38576928</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Y., Huang L. Neurological Disorders following COVID-19 Vaccination. Vaccines. 2023;11:1114. doi: 10.3390/vaccines11061114.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines11061114</ArticleId><ArticleId IdType="pmc">PMC10302665</ArticleId><ArticleId IdType="pubmed">37376503</ArticleId></ArticleIdList></Reference><Reference><Citation>Oo W.M., Giri P., de Souza A. AstraZeneca COVID-19 vaccine and Guillain- Barre Syndrome in Tasmania: A causal link? J. Neuroimmunol. 2021;360:577719. doi: 10.1016/j.jneuroim.2021.577719.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jneuroim.2021.577719</ArticleId><ArticleId IdType="pmc">PMC8447540</ArticleId><ArticleId IdType="pubmed">34560365</ArticleId></ArticleIdList></Reference><Reference><Citation>Hilts A., Schreiber A., Singh A. A Clinical Case of COVID-19 Vaccine-Associated Guillain-Barre Syndrome. Am. J. Case Rep. 2022;23:e936896. doi: 10.12659/AJCR.936896.</Citation><ArticleIdList><ArticleId IdType="doi">10.12659/AJCR.936896</ArticleId><ArticleId IdType="pmc">PMC9377719</ArticleId><ArticleId IdType="pubmed">35945825</ArticleId></ArticleIdList></Reference><Reference><Citation>Khurshid M., Ansari I., Ahmad H., Ghaffar H., Khurshid A., Shahid A., Essar M.Y., Ullah I., Cheema H.A. Development of facial palsy following COVID-19 vaccination: A systematic review. Ann. Med. Surg. 2022;82:104758. doi: 10.1016/j.amsu.2022.104758.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amsu.2022.104758</ArticleId><ArticleId IdType="pmc">PMC9530738</ArticleId><ArticleId IdType="pubmed">36212732</ArticleId></ArticleIdList></Reference><Reference><Citation>Mansour K., Chadli Z., Ghachem I., Fredj N.B., Romdhane H.B., Fadhel N.B., Boughatas N., Aouam K., Chaabane A., Younes S. Seronegative acute encephalitis following COVID-19 vaccines: A case series of an overlooked diagnosis with literature review. Eur. J. Clin. Pharmacol. 2023;79:975&#x2013;987. doi: 10.1007/s00228-023-03510-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00228-023-03510-7</ArticleId><ArticleId IdType="pmc">PMC10212735</ArticleId><ArticleId IdType="pubmed">37231308</ArticleId></ArticleIdList></Reference><Reference><Citation>Abbott M.G., Allawi Z., Hofer M., Ansorge O., Brady S., Fadic R., Torres G., Knight R., Calvo M., Bennett D.L.H., et al. Acute small fiber neuropathy after Oxford-AstraZeneca ChAdOx1-S vaccination: A report of three cases and review of the literature. J. Peripher. Nerv. Syst. 2022;27:325&#x2013;329. doi: 10.1111/jns.12509.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jns.12509</ArticleId><ArticleId IdType="pmc">PMC9538519</ArticleId><ArticleId IdType="pubmed">35962630</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrenko V.A., Gillespie J.W., De Plano L.M., Shokhen M.A. Phage-Displayed Mimotopes of SARS-CoV-2 Spike Protein Targeted to Authentic and Alternative Cellular Receptors. Viruses. 2022;14:384. doi: 10.3390/v14020384.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v14020384</ArticleId><ArticleId IdType="pmc">PMC8879608</ArticleId><ArticleId IdType="pubmed">35215976</ArticleId></ArticleIdList></Reference><Reference><Citation>Asadi-Pooya A.A., Akbari A., Emami A., Lotfi M., Rostamihosseinkhani M., Nemati H., Barzegar Z., Kabiri M., Zeraatpisheh Z., Farjoud-Kouhanjani M., et al. Risk Factors Associated with Long COVID Syndrome: A Retrospective Study. Iran. J. Med. Sci. 2021;46:428&#x2013;436. doi: 10.30476/ijms.2021.92080.2326.</Citation><ArticleIdList><ArticleId IdType="doi">10.30476/ijms.2021.92080.2326</ArticleId><ArticleId IdType="pmc">PMC8611223</ArticleId><ArticleId IdType="pubmed">34840383</ArticleId></ArticleIdList></Reference><Reference><Citation>Natarajan A., Shetty A., Delanerolle G., Zeng Y., Zhang Y., Raymont V., Rathod S., Halabi S., Elliot K., Shi J.Q., et al. A systematic review and meta-analysis of long COVID symptoms. Syst. Rev. 2023;12:88. doi: 10.1186/s13643-023-02250-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13643-023-02250-0</ArticleId><ArticleId IdType="pmc">PMC10220332</ArticleId><ArticleId IdType="pubmed">37245047</ArticleId></ArticleIdList></Reference><Reference><Citation>Woodrow M., Carey C., Ziauddeen N., Thomas R., Akrami A., Lutje V., Greenwood D.C., Alwan N.A. Systematic Review of the Prevalence of Long COVID. Open Forum Infect. Dis. 2023;10:ofad233. doi: 10.1093/ofid/ofad233.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofad233</ArticleId><ArticleId IdType="pmc">PMC10316694</ArticleId><ArticleId IdType="pubmed">37404951</ArticleId></ArticleIdList></Reference><Reference><Citation>Coburn C.M., Eger E.I., 2nd The partial pressure of isoflurane or halothane does not affect their solubility in rabbit blood or brain or human brain: Inhaled anesthetics obey Henry&#x2019;s Law. Anesth. Analg. 1986;65:960&#x2013;962. doi: 10.1213/00000539-198609000-00009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1213/00000539-198609000-00009</ArticleId><ArticleId IdType="pubmed">3740495</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis H.E., McCorkell L., Vogel J.M., Topol E.J. Long COVID: Major findings, mechanisms and recommendations. Nat. Rev. Microbiol. 2023;21:133&#x2013;146. doi: 10.1038/s41579-022-00846-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-022-00846-2</ArticleId><ArticleId IdType="pmc">PMC9839201</ArticleId><ArticleId IdType="pubmed">36639608</ArticleId></ArticleIdList></Reference><Reference><Citation>Gheorghita R., Soldanescu I., Lobiuc A., Caliman Sturdza O.A., Filip R., Constantinescu-Bercu A., Dimian M., Mangul S., Covasa M. The knowns and unknowns of long COVID-19: From mechanisms to therapeutical approaches. Front. Immunol. 2024;15:1344086. doi: 10.3389/fimmu.2024.1344086.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2024.1344086</ArticleId><ArticleId IdType="pmc">PMC10944866</ArticleId><ArticleId IdType="pubmed">38500880</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsampasian V., Elghazaly H., Chattopadhyay R., Debski M., Naing T.K.P., Garg P., Clark A., Ntatsaki E., Vassiliou V.S. Risk Factors Associated With Post-COVID-19 Condition: A Systematic Review and Meta-analysis. JAMA Intern. Med. 2023;183:566&#x2013;580. doi: 10.1001/jamainternmed.2023.0750.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2023.0750</ArticleId><ArticleId IdType="pmc">PMC10037203</ArticleId><ArticleId IdType="pubmed">36951832</ArticleId></ArticleIdList></Reference><Reference><Citation>Theoharides T.C. Could SARS-CoV-2 Spike Protein Be Responsible for Long-COVID Syndrome? Mol. Neurobiol. 2022;59:1850&#x2013;1861. doi: 10.1007/s12035-021-02696-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-021-02696-0</ArticleId><ArticleId IdType="pmc">PMC8757925</ArticleId><ArticleId IdType="pubmed">35028901</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L., Zhou L., Bao L., Liu J., Zhu H., Lv Q., Liu R., Chen W., Tong W., Wei Q., et al. SARS-CoV-2 crosses the blood-brain barrier accompanied with basement membrane disruption without tight junctions alteration. Signal Transduct. Target. Ther. 2021;6:337. doi: 10.1038/s41392-021-00719-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-021-00719-9</ArticleId><ArticleId IdType="pmc">PMC8419672</ArticleId><ArticleId IdType="pubmed">34489403</ArticleId></ArticleIdList></Reference><Reference><Citation>Catala M., Mercade-Besora N., Kolde R., Trinh N.T.H., Roel E., Burn E., Rathod-Mistry T., Kostka K., Man W.Y., Delmestri A., et al. The effectiveness of COVID-19 vaccines to prevent long COVID symptoms: Staggered cohort study of data from the UK, Spain, and Estonia. Lancet Respir. Med. 2024;12:225&#x2013;236. doi: 10.1016/S2213-2600(23)00414-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(23)00414-9</ArticleId><ArticleId IdType="pubmed">38219763</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe A., Iwagami M., Yasuhara J., Takagi H., Kuno T. Protective effect of COVID-19 vaccination against long COVID syndrome: A systematic review and meta-analysis. Vaccine. 2023;41:1783&#x2013;1790. doi: 10.1016/j.vaccine.2023.02.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2023.02.008</ArticleId><ArticleId IdType="pmc">PMC9905096</ArticleId><ArticleId IdType="pubmed">36774332</ArticleId></ArticleIdList></Reference><Reference><Citation>Byambasuren O., Stehlik P., Clark J., Alcorn K., Glasziou P. Effect of COVID-19 vaccination on long COVID: Systematic review. BMJ Med. 2023;2:e000385. doi: 10.1136/bmjmed-2022-000385.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjmed-2022-000385</ArticleId><ArticleId IdType="pmc">PMC9978692</ArticleId><ArticleId IdType="pubmed">36936268</ArticleId></ArticleIdList></Reference><Reference><Citation>Ceban F., Kulzhabayeva D., Rodrigues N.B., Di Vincenzo J.D., Gill H., Subramaniapillai M., Lui L.M.W., Cao B., Mansur R.B., Ho R.C., et al. COVID-19 vaccination for the prevention and treatment of long COVID: A systematic review and meta-analysis. Brain Behav. Immun. 2023;111:211&#x2013;229. doi: 10.1016/j.bbi.2023.03.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2023.03.022</ArticleId><ArticleId IdType="pmc">PMC10067136</ArticleId><ArticleId IdType="pubmed">36990297</ArticleId></ArticleIdList></Reference><Reference><Citation>Notarte K.I., Catahay J.A., Velasco J.V., Pastrana A., Ver A.T., Pangilinan F.C., Peligro P.J., Casimiro M., Guerrero J.J., Gellaco M.M.L., et al. Impact of COVID-19 vaccination on the risk of developing long-COVID and on existing long-COVID symptoms: A systematic review. EClinicalMedicine. 2022;53:101624. doi: 10.1016/j.eclinm.2022.101624.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2022.101624</ArticleId><ArticleId IdType="pmc">PMC9417563</ArticleId><ArticleId IdType="pubmed">36051247</ArticleId></ArticleIdList></Reference><Reference><Citation>Romeiser J.L., Schoeneck K. COVID-19 Booster Vaccination Status and Long COVID in the United States: A Nationally Representative Cross-Sectional Study. Vaccines. 2024;12:688. doi: 10.3390/vaccines12060688.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines12060688</ArticleId><ArticleId IdType="pmc">PMC11209278</ArticleId><ArticleId IdType="pubmed">38932418</ArticleId></ArticleIdList></Reference><Reference><Citation>Marra A.R., Kobayashi T., Callado G.Y., Pardo I., Gutfreund M.C., Hsieh M.K., Lin V., Alsuhaibani M., Hasegawa S., Tholany J., et al. The effectiveness of COVID-19 vaccine in the prevention of post-COVID conditions: A systematic literature review and meta-analysis of the latest research. Antimicrob. Steward. Healthc. Epidemiol. 2023;3:e168. doi: 10.1017/ash.2023.447.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/ash.2023.447</ArticleId><ArticleId IdType="pmc">PMC10644173</ArticleId><ArticleId IdType="pubmed">38028898</ArticleId></ArticleIdList></Reference><Reference><Citation>Kashte S., Gulbake A., El-Amin Iii S.F., Gupta A. COVID-19 vaccines: Rapid development, implications, challenges and future prospects. Hum. Cell. 2021;34:711&#x2013;733. doi: 10.1007/s13577-021-00512-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13577-021-00512-4</ArticleId><ArticleId IdType="pmc">PMC7937046</ArticleId><ArticleId IdType="pubmed">33677814</ArticleId></ArticleIdList></Reference><Reference><Citation>Wagner R., Hildt E., Grabski E., Sun Y., Meyer H., Lommel A., Keller-Stanislawski B., Muller-Berghaus J., Cichutek K. Accelerated Development of COVID-19 Vaccines: Technology Platforms, Benefits, and Associated Risks. Vaccines. 2021;9:747. doi: 10.3390/vaccines9070747.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines9070747</ArticleId><ArticleId IdType="pmc">PMC8310218</ArticleId><ArticleId IdType="pubmed">34358163</ArticleId></ArticleIdList></Reference><Reference><Citation>Cui X., Wang P., Wei Z. Emergency use of COVID-19 vaccines recommended by the World Health Organization (WHO) as of June 2021. Drug Discov. Ther. 2021;15:222&#x2013;224. doi: 10.5582/ddt.2021.01064.</Citation><ArticleIdList><ArticleId IdType="doi">10.5582/ddt.2021.01064</ArticleId><ArticleId IdType="pubmed">34275974</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballini L., Wild C., Djuric O., Mayer-Ferbas J., Willemsen A., Huic M., Group E.U.C.-T.F. European Network for Health Technology Assessment&#x2019;s Response to COVID-19: Rapid Collaborative Reviews on Diagnostic Tests and Rolling and Rapid Collaborative Reviews on Therapeutics. Int. J. Technol. Assess. Health Care. 2022;38:e22. doi: 10.1017/S0266462322000071.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S0266462322000071</ArticleId><ArticleId IdType="pubmed">35477493</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein K., Stolk P., Tellner P., Acha V., Montagne S., Stockert I. Regulatory Flexibilities and Guidances for Addressing the Challenges of COVID-19 in the EU: What Can We Learn from Company Experiences? Ther. Innov. Regul. Sci. 2022;56:366&#x2013;377. doi: 10.1007/s43441-022-00383-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s43441-022-00383-3</ArticleId><ArticleId IdType="pmc">PMC8821789</ArticleId><ArticleId IdType="pubmed">35129827</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO  COVID-19 Advice for the Public: Getting Vaccinated.  [(accessed on 15 September 2024)].  Available online:  https://www.who.int/emergencies/diseases/novel-coronavirus-2019/covid-19-vaccines/advice.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>